



## 104TH GENERAL ASSEMBLY

### State of Illinois

2025 and 2026

SB1773

Introduced 2/5/2025, by Sen. Julie A. Morrison

#### SYNOPSIS AS INTRODUCED:

|                  |                            |
|------------------|----------------------------|
| 720 ILCS 570/102 | from Ch. 56 1/2, par. 1102 |
| 720 ILCS 570/204 | from Ch. 56 1/2, par. 1204 |
| 720 ILCS 570/206 | from Ch. 56 1/2, par. 1206 |
| 720 ILCS 570/208 | from Ch. 56 1/2, par. 1208 |

Amends the Illinois Controlled Substances Act. Makes structural and other changes to the list of controlled substances. Adds xylazine as a Class III controlled substance. Defines "isomer". Effective January 1, 2026.

LRB104 03029 RLC 13047 b

1 AN ACT concerning criminal law.

2 **Be it enacted by the People of the State of Illinois,**  
3 **represented in the General Assembly:**

4 Section 5. The Illinois Controlled Substances Act is  
5 amended by changing Sections 102, 204, 206, and 208 as  
6 follows:

7 (720 ILCS 570/102) (from Ch. 56 1/2, par. 1102)

8 (Text of Section before amendment by P.A. 103-881)

9 Sec. 102. Definitions. As used in this Act, unless the  
10 context otherwise requires:

11 (a) "Addict" means any person who habitually uses any  
12 drug, chemical, substance or dangerous drug other than alcohol  
13 so as to endanger the public morals, health, safety or welfare  
14 or who is so far addicted to the use of a dangerous drug or  
15 controlled substance other than alcohol as to have lost the  
16 power of self control with reference to his or her addiction.

17 (b) "Administer" means the direct application of a  
18 controlled substance, whether by injection, inhalation,  
19 ingestion, or any other means, to the body of a patient,  
20 research subject, or animal (as defined by the Humane  
21 Euthanasia in Animal Shelters Act) by:

22 (1) a practitioner (or, in his or her presence, by his  
23 or her authorized agent),

1           (2) the patient or research subject pursuant to an  
2           order, or

3           (3) a euthanasia technician as defined by the Humane  
4           Euthanasia in Animal Shelters Act.

5           (c) "Agent" means an authorized person who acts on behalf  
6           of or at the direction of a manufacturer, distributor,  
7           dispenser, prescriber, or practitioner. It does not include a  
8           common or contract carrier, public warehouseman or employee of  
9           the carrier or warehouseman.

10          (c-1) "Anabolic Steroids" means any drug or hormonal  
11          substance, chemically and pharmacologically related to  
12          testosterone (other than estrogens, progestins,  
13          corticosteroids, and dehydroepiandrosterone), and includes:

- 14           (i) 3[beta],17-dihydroxy-5a-androstane,  
15           (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,  
16           (iii) 5[alpha]-androstan-3,17-dione,  
17           (iv) 1-androstenediol (3[beta],  
18               17[beta]-dihydroxy-5[alpha]-androst-1-ene),  
19           (v) 1-androstenediol (3[alpha],  
20               17[beta]-dihydroxy-5[alpha]-androst-1-ene),  
21           (vi) 4-androstenediol  
22               (3[beta],17[beta]-dihydroxy-androst-4-ene),  
23           (vii) 5-androstenediol  
24               (3[beta],17[beta]-dihydroxy-androst-5-ene),  
25           (viii) 1-androstenedione  
26               ([5alpha]-androst-1-en-3,17-dione),

1 (ix) 4-androstenedione  
2 (androst-4-en-3,17-dione),  
3 (x) 5-androstenedione  
4 (androst-5-en-3,17-dione),  
5 (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-  
6 hydroxyandrost-4-en-3-one),  
7 (xii) boldenone (17[beta]-hydroxyandrost-  
8 1,4,-diene-3-one),  
9 (xiii) boldione (androsta-1,4-  
10 diene-3,17-dione),  
11 (xiv) calusterone (7[beta],17[alpha]-dimethyl-17  
12 [beta]-hydroxyandrost-4-en-3-one),  
13 (xv) clostebol (4-chloro-17[beta]-  
14 hydroxyandrost-4-en-3-one),  
15 (xvi) dehydrochloromethyltestosterone (4-chloro-  
16 17[beta]-hydroxy-17[alpha]-methyl-  
17 androst-1,4-dien-3-one),  
18 (xvii) desoxymethyltestosterone  
19 (17[alpha]-methyl-5[alpha]  
20 -androst-2-en-17[beta]-ol) (a.k.a., madol),  
21 (xviii) [delta]1-dihydrotestosterone (a.k.a.  
22 '1-testosterone') (17[beta]-hydroxy-  
23 5[alpha]-androst-1-en-3-one),  
24 (xix) 4-dihydrotestosterone (17[beta]-hydroxy-  
25 androstan-3-one),  
26 (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-

1           5[alpha]-androstan-3-one),  
2        (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-  
3           hydroxyestr-4-ene),  
4        (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-  
5           1[beta],17[beta]-dihydroxyandrost-4-en-3-one),  
6        (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],  
7           17[beta]-dihydroxyandrost-1,4-dien-3-one),  
8        (xxiv) furazabol (17[alpha]-methyl-17[beta]-  
9           hydroxyandrostando[2,3-c]-furazan),  
10       (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,  
11       (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-  
12           androst-4-en-3-one),  
13       (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-  
14           dihydroxy-estr-4-en-3-one),  
15       (xxviii) mestanolone (17[alpha]-methyl-17[beta]-  
16           hydroxy-5-androstan-3-one),  
17       (xxix) mesterolone (1-methyl-17[beta]-hydroxy-  
18           [5a]-androstan-3-one),  
19       (xxx) methandienone (17[alpha]-methyl-17[beta]-  
20           hydroxyandrost-1,4-dien-3-one),  
21       (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-  
22           dihydroxyandrost-5-ene),  
23       (xxxii) methenolone (1-methyl-17[beta]-hydroxy-  
24           5[alpha]-androst-1-en-3-one),  
25       (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-  
26           dihydroxy-5a-androstane,

(xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy  
-5a-androstane,  
(xxxv) 17[alpha]-methyl-3[beta],17[beta]-  
dihydroxyandrost-4-ene),  
(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-  
methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),  
(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-  
hydroxyestra-4,9(10)-dien-3-one),  
(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-  
hydroxyestra-4,9-11-trien-3-one),  
(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-  
hydroxyandrost-4-en-3-one),  
(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-  
hydroxyestr-4-en-3-one),  
(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
(17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-  
androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-  
1-testosterone'),  
(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),  
(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-  
dihydroxyestr-4-ene),  
(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-  
dihydroxyestr-4-ene),  
(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-  
dihydroxyestr-5-ene),  
(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-

1 dihydroxyestr-5-ene),  
2 (xlvii) 19-nor-4,9(10)-androstadienedione  
3 (estra-4,9(10)-diene-3,17-dione),  
4 (xlviii) 19-nor-4-androstenedione (estr-4-  
5 en-3,17-dione),  
6 (xlix) 19-nor-5-androstenedione (estr-5-  
7 en-3,17-dione),  
8 (l) norbolethone (13[beta], 17a-diethyl-17[beta]-  
9 hydroxygon-4-en-3-one),  
10 (li) norclostebol (4-chloro-17[beta]-  
11 hydroxyestr-4-en-3-one),  
12 (lii) norethandrolone (17[alpha]-ethyl-17[beta]-  
13 hydroxyestr-4-en-3-one),  
14 (liii) normethandrolone (17[alpha]-methyl-17[beta]-  
15 hydroxyestr-4-en-3-one),  
16 (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-  
17 2-oxa-5[alpha]-androstan-3-one),  
18 (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-  
19 dihydroxyandrost-4-en-3-one),  
20 (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-  
21 17[beta]-hydroxy-(5[alpha]-androstan-3-one),  
22 (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-  
23 (5[alpha]-androst-2-eno[3,2-c]-pyrazole),  
24 (lviii) stenbolone (17[beta]-hydroxy-2-methyl-  
25 (5[alpha]-androst-1-en-3-one),  
26 (lix) testolactone (13-hydroxy-3-oxo-13,17-

1           secoandrosta-1,4-dien-17-oic  
2           acid lactone),  
3       (lx) testosterone (17[beta]-hydroxyandrost-  
4           4-en-3-one),  
5       (lxi) tetrahydrogestrinone (13[beta], 17[alpha]-  
6           diethyl-17[beta]-hydroxygon-  
7           4,9,11-trien-3-one),  
8       (lxii) trenbolone (17[beta]-hydroxyestr-4,9,  
9           11-trien-3-one).

10       Any person who is otherwise lawfully in possession of an  
11       anabolic steroid, or who otherwise lawfully manufactures,  
12       distributes, dispenses, delivers, or possesses with intent to  
13       deliver an anabolic steroid, which anabolic steroid is  
14       expressly intended for and lawfully allowed to be administered  
15       through implants to livestock or other nonhuman species, and  
16       which is approved by the Secretary of Health and Human  
17       Services for such administration, and which the person intends  
18       to administer or have administered through such implants,  
19       shall not be considered to be in unauthorized possession or to  
20       unlawfully manufacture, distribute, dispense, deliver, or  
21       possess with intent to deliver such anabolic steroid for  
22       purposes of this Act.

23       (d) "Administration" means the Drug Enforcement  
24       Administration, United States Department of Justice, or its  
25       successor agency.

26       (d-5) "Clinical Director, Prescription Monitoring Program"



1 means a Department of Human Services administrative employee  
2 licensed to either prescribe or dispense controlled substances  
3 who shall run the clinical aspects of the Department of Human  
4 Services Prescription Monitoring Program and its Prescription  
5 Information Library.

6 (d-10) "Compounding" means the preparation and mixing of  
7 components, excluding flavorings, (1) as the result of a  
8 prescriber's prescription drug order or initiative based on  
9 the prescriber-patient-pharmacist relationship in the course  
10 of professional practice or (2) for the purpose of, or  
11 incident to, research, teaching, or chemical analysis and not  
12 for sale or dispensing. "Compounding" includes the preparation  
13 of drugs or devices in anticipation of receiving prescription  
14 drug orders based on routine, regularly observed dispensing  
15 patterns. Commercially available products may be compounded  
16 for dispensing to individual patients only if both of the  
17 following conditions are met: (i) the commercial product is  
18 not reasonably available from normal distribution channels in  
19 a timely manner to meet the patient's needs and (ii) the  
20 prescribing practitioner has requested that the drug be  
21 compounded.

22 (e) "Control" means to add a drug or other substance, or  
23 immediate precursor, to a Schedule whether by transfer from  
24 another Schedule or otherwise.

25 (f) "Controlled Substance" means (i) a drug, substance,  
26 immediate precursor, or synthetic drug in the Schedules of

1 Article II of this Act or (ii) a drug or other substance, or  
2 immediate precursor, designated as a controlled substance by  
3 the Department through administrative rule. The term does not  
4 include distilled spirits, wine, malt beverages, or tobacco,  
5 as those terms are defined or used in the Liquor Control Act of  
6 1934 and the Tobacco Products Tax Act of 1995.

7 (f-5) "Controlled substance analog" means a substance:

8 (1) the chemical structure of which is substantially  
9 similar to the chemical structure of a controlled  
10 substance in Schedule I or II;

11 (2) which has a stimulant, depressant, or  
12 hallucinogenic effect on the central nervous system that  
13 is substantially similar to or greater than the stimulant,  
14 depressant, or hallucinogenic effect on the central  
15 nervous system of a controlled substance in Schedule I or  
16 II; or

17 (3) with respect to a particular person, which such  
18 person represents or intends to have a stimulant,  
19 depressant, or hallucinogenic effect on the central  
20 nervous system that is substantially similar to or greater  
21 than the stimulant, depressant, or hallucinogenic effect  
22 on the central nervous system of a controlled substance in  
23 Schedule I or II.

24 (g) "Counterfeit substance" means a controlled substance,  
25 which, or the container or labeling of which, without  
26 authorization bears the trademark, trade name, or other

1 identifying mark, imprint, number or device, or any likeness  
2 thereof, of a manufacturer, distributor, or dispenser other  
3 than the person who in fact manufactured, distributed, or  
4 dispensed the substance.

5 (h) "Deliver" or "delivery" means the actual, constructive  
6 or attempted transfer of possession of a controlled substance,  
7 with or without consideration, whether or not there is an  
8 agency relationship. "Deliver" or "delivery" does not include  
9 the donation of drugs to the extent permitted under the  
10 Illinois Drug Reuse Opportunity Program Act.

11 (i) "Department" means the Illinois Department of Human  
12 Services (as successor to the Department of Alcoholism and  
13 Substance Abuse) or its successor agency.

14 (j) (Blank).

15 (k) "Department of Corrections" means the Department of  
16 Corrections of the State of Illinois or its successor agency.

17 (l) "Department of Financial and Professional Regulation"  
18 means the Department of Financial and Professional Regulation  
19 of the State of Illinois or its successor agency.

20 (m) "Depressant" means any drug that (i) causes an overall  
21 depression of central nervous system functions, (ii) causes  
22 impaired consciousness and awareness, and (iii) can be  
23 habit-forming or lead to a substance abuse problem, including,  
24 but not limited to, alcohol, cannabis and its active  
25 principles and their analogs, benzodiazepines and their  
26 analogs, barbiturates and their analogs, opioids (natural and

1 synthetic) and their analogs, and chloral hydrate and similar  
2 sedative hypnotics.

3 (n) (Blank).

4 (o) "Director" means the Director of the Illinois State  
5 Police or his or her designated agents.

6 (p) "Dispense" means to deliver a controlled substance to  
7 an ultimate user or research subject by or pursuant to the  
8 lawful order of a prescriber, including the prescribing,  
9 administering, packaging, labeling, or compounding necessary  
10 to prepare the substance for that delivery.

11 (q) "Dispenser" means a practitioner who dispenses.

12 (r) "Distribute" means to deliver, other than by  
13 administering or dispensing, a controlled substance.

14 (s) "Distributor" means a person who distributes.

15 (t) "Drug" means (1) substances recognized as drugs in the  
16 official United States Pharmacopoeia, Official Homeopathic  
17 Pharmacopoeia of the United States, or official National  
18 Formulary, or any supplement to any of them; (2) substances  
19 intended for use in diagnosis, cure, mitigation, treatment, or  
20 prevention of disease in man or animals; (3) substances (other  
21 than food) intended to affect the structure of any function of  
22 the body of man or animals and (4) substances intended for use  
23 as a component of any article specified in clause (1), (2), or  
24 (3) of this subsection. It does not include devices or their  
25 components, parts, or accessories.

26 (t-3) "Electronic health record" or "EHR" means an

1 electronic record of health-related information on an  
2 individual that is created, gathered, managed, and consulted  
3 by authorized health care clinicians and staff.

4 (t-3.5) "Electronic health record system" or "EHR system"  
5 means any computer-based system or combination of federally  
6 certified Health IT Modules (defined at 42 CFR 170.102 or its  
7 successor) used as a repository for electronic health records  
8 and accessed or updated by a prescriber or authorized  
9 surrogate in the ordinary course of his or her medical  
10 practice. For purposes of connecting to the Prescription  
11 Information Library maintained by the Bureau of Pharmacy and  
12 Clinical Support Systems or its successor, an EHR system may  
13 connect to the Prescription Information Library directly or  
14 through all or part of a computer program or system that is a  
15 federally certified Health IT Module maintained by a third  
16 party and used by the EHR system to secure access to the  
17 database.

18 (t-4) "Emergency medical services personnel" has the  
19 meaning ascribed to it in the Emergency Medical Services (EMS)  
20 Systems Act.

21 (t-5) "Euthanasia agency" means an entity certified by the  
22 Department of Financial and Professional Regulation for the  
23 purpose of animal euthanasia that holds an animal control  
24 facility license or animal shelter license under the Animal  
25 Welfare Act. A euthanasia agency is authorized to purchase,  
26 store, possess, and utilize Schedule II nonnarcotic and

1 Schedule III nonnarcotic drugs for the sole purpose of animal  
2 euthanasia.

3 (t-10) "Euthanasia drugs" means Schedule II or Schedule  
4 III substances (nonnarcotic controlled substances) that are  
5 used by a euthanasia agency for the purpose of animal  
6 euthanasia.

7 (u) "Good faith" means the prescribing or dispensing of a  
8 controlled substance by a practitioner in the regular course  
9 of professional treatment to or for any person who is under his  
10 or her treatment for a pathology or condition other than that  
11 individual's physical or psychological dependence upon or  
12 addiction to a controlled substance, except as provided  
13 herein: and application of the term to a pharmacist shall mean  
14 the dispensing of a controlled substance pursuant to the  
15 prescriber's order which in the professional judgment of the  
16 pharmacist is lawful. The pharmacist shall be guided by  
17 accepted professional standards, including, but not limited  
18 to, the following, in making the judgment:

19 (1) lack of consistency of prescriber-patient  
20 relationship,

21 (2) frequency of prescriptions for same drug by one  
22 prescriber for large numbers of patients,

23 (3) quantities beyond those normally prescribed,

24 (4) unusual dosages (recognizing that there may be  
25 clinical circumstances where more or less than the usual  
26 dose may be used legitimately),

1           (5) unusual geographic distances between patient,  
2           pharmacist and prescriber,

3           (6) consistent prescribing of habit-forming drugs.

4           (u-0.5) "Hallucinogen" means a drug that causes markedly  
5           altered sensory perception leading to hallucinations of any  
6           type.

7           (u-1) "Home infusion services" means services provided by  
8           a pharmacy in compounding solutions for direct administration  
9           to a patient in a private residence, long-term care facility,  
10          or hospice setting by means of parenteral, intravenous,  
11          intramuscular, subcutaneous, or intraspinal infusion.

12          (u-5) "Illinois State Police" means the Illinois State  
13          Police or its successor agency.

14          (v) "Immediate precursor" means a substance:

15               (1) which the Department has found to be and by rule  
16               designated as being a principal compound used, or produced  
17               primarily for use, in the manufacture of a controlled  
18               substance;

19               (2) which is an immediate chemical intermediary used  
20               or likely to be used in the manufacture of such controlled  
21               substance; and

22               (3) the control of which is necessary to prevent,  
23               curtail or limit the manufacture of such controlled  
24               substance.

25          (w) "Instructional activities" means the acts of teaching,  
26          educating or instructing by practitioners using controlled

1 substances within educational facilities approved by the State  
2 Board of Education or its successor agency.

3 (x) "Local authorities" means a duly organized State,  
4 County or Municipal peace unit or police force.

5 (y) "Look-alike substance" means a substance, other than a  
6 controlled substance which (1) by overall dosage unit  
7 appearance, including shape, color, size, markings or lack  
8 thereof, taste, consistency, or any other identifying physical  
9 characteristic of the substance, would lead a reasonable  
10 person to believe that the substance is a controlled  
11 substance, or (2) is expressly or impliedly represented to be  
12 a controlled substance or is distributed under circumstances  
13 which would lead a reasonable person to believe that the  
14 substance is a controlled substance. For the purpose of  
15 determining whether the representations made or the  
16 circumstances of the distribution would lead a reasonable  
17 person to believe the substance to be a controlled substance  
18 under this clause (2) of subsection (y), the court or other  
19 authority may consider the following factors in addition to  
20 any other factor that may be relevant:

21 (a) statements made by the owner or person in control  
22 of the substance concerning its nature, use or effect;

23 (b) statements made to the buyer or recipient that the  
24 substance may be resold for profit;

25 (c) whether the substance is packaged in a manner  
26 normally used for the illegal distribution of controlled



1 substances;

2 (d) whether the distribution or attempted distribution  
3 included an exchange of or demand for money or other  
4 property as consideration, and whether the amount of the  
5 consideration was substantially greater than the  
6 reasonable retail market value of the substance.

7 Clause (1) of this subsection (y) shall not apply to a  
8 noncontrolled substance in its finished dosage form that was  
9 initially introduced into commerce prior to the initial  
10 introduction into commerce of a controlled substance in its  
11 finished dosage form which it may substantially resemble.

12 Nothing in this subsection (y) prohibits the dispensing or  
13 distributing of noncontrolled substances by persons authorized  
14 to dispense and distribute controlled substances under this  
15 Act, provided that such action would be deemed to be carried  
16 out in good faith under subsection (u) if the substances  
17 involved were controlled substances.

18 Nothing in this subsection (y) or in this Act prohibits  
19 the manufacture, preparation, propagation, compounding,  
20 processing, packaging, advertising or distribution of a drug  
21 or drugs by any person registered pursuant to Section 510 of  
22 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

23 (y-1) "Mail-order pharmacy" means a pharmacy that is  
24 located in a state of the United States that delivers,  
25 dispenses or distributes, through the United States Postal  
26 Service or other common carrier, to Illinois residents, any

1 substance which requires a prescription.

2 (z) "Manufacture" means the production, preparation,  
3 propagation, compounding, conversion or processing of a  
4 controlled substance other than methamphetamine, either  
5 directly or indirectly, by extraction from substances of  
6 natural origin, or independently by means of chemical  
7 synthesis, or by a combination of extraction and chemical  
8 synthesis, and includes any packaging or repackaging of the  
9 substance or labeling of its container, except that this term  
10 does not include:

11 (1) by an ultimate user, the preparation or  
12 compounding of a controlled substance for his or her own  
13 use;

14 (2) by a practitioner, or his or her authorized agent  
15 under his or her supervision, the preparation,  
16 compounding, packaging, or labeling of a controlled  
17 substance:

18 (a) as an incident to his or her administering or  
19 dispensing of a controlled substance in the course of  
20 his or her professional practice; or

21 (b) as an incident to lawful research, teaching or  
22 chemical analysis and not for sale; or

23 (3) the packaging, repackaging, or labeling of drugs  
24 only to the extent permitted under the Illinois Drug Reuse  
25 Opportunity Program Act.

26 (z-1) (Blank).

1       (z-5) "Medication shopping" means the conduct prohibited  
2 under subsection (a) of Section 314.5 of this Act.

3       (z-10) "Mid-level practitioner" means (i) a physician  
4 assistant who has been delegated authority to prescribe  
5 through a written delegation of authority by a physician  
6 licensed to practice medicine in all of its branches, in  
7 accordance with Section 7.5 of the Physician Assistant  
8 Practice Act of 1987, (ii) an advanced practice registered  
9 nurse who has been delegated authority to prescribe through a  
10 written delegation of authority by a physician licensed to  
11 practice medicine in all of its branches or by a podiatric  
12 physician, in accordance with Section 65-40 of the Nurse  
13 Practice Act, (iii) an advanced practice registered nurse  
14 certified as a nurse practitioner, nurse midwife, or clinical  
15 nurse specialist who has been granted authority to prescribe  
16 by a hospital affiliate in accordance with Section 65-45 of  
17 the Nurse Practice Act, (iv) an animal euthanasia agency, or  
18 (v) a prescribing psychologist.

19       (aa) "Narcotic drug" means any of the following, whether  
20 produced directly or indirectly by extraction from substances  
21 of vegetable origin, or independently by means of chemical  
22 synthesis, or by a combination of extraction and chemical  
23 synthesis:

24           (1) opium, opiates, derivatives of opium and opiates,  
25 including their isomers, esters, ethers, salts, and salts  
26 of isomers, esters, and ethers, whenever the existence of

1 such isomers, esters, ethers, and salts is possible within  
2 the specific chemical designation; however the term  
3 "narcotic drug" does not include the isoquinoline  
4 alkaloids of opium;

5 (2) (blank);

6 (3) opium poppy and poppy straw;

7 (4) coca leaves, except coca leaves and extracts of  
8 coca leaves from which substantially all of the cocaine  
9 and ecgonine, and their isomers, derivatives and salts,  
10 have been removed;

11 (5) cocaine, its salts, optical and geometric isomers,  
12 and salts of isomers;

13 (6) ecgonine, its derivatives, their salts, isomers,  
14 and salts of isomers;

15 (7) any compound, mixture, or preparation which  
16 contains any quantity of any of the substances referred to  
17 in subparagraphs (1) through (6).

18 (bb) "Nurse" means a registered nurse licensed under the  
19 Nurse Practice Act.

20 (cc) (Blank).

21 (dd) "Opiate" means any substance having an addiction  
22 forming or addiction sustaining liability similar to morphine  
23 or being capable of conversion into a drug having addiction  
24 forming or addiction sustaining liability.

25 (ee) "Opium poppy" means the plant of the species *Papaver*  
26 *somniferum* L., except its seeds.

1           (ee-5) "Oral dosage" means a tablet, capsule, elixir, or  
2           solution or other liquid form of medication intended for  
3           administration by mouth, but the term does not include a form  
4           of medication intended for buccal, sublingual, or transmucosal  
5           administration.

6           (ff) "Parole and Pardon Board" means the Parole and Pardon  
7           Board of the State of Illinois or its successor agency.

8           (gg) "Person" means any individual, corporation,  
9           mail-order pharmacy, government or governmental subdivision or  
10          agency, business trust, estate, trust, partnership or  
11          association, or any other entity.

12          (hh) "Pharmacist" means any person who holds a license or  
13          certificate of registration as a registered pharmacist, a  
14          local registered pharmacist or a registered assistant  
15          pharmacist under the Pharmacy Practice Act.

16          (ii) "Pharmacy" means any store, ship or other place in  
17          which pharmacy is authorized to be practiced under the  
18          Pharmacy Practice Act.

19          (ii-5) "Pharmacy shopping" means the conduct prohibited  
20          under subsection (b) of Section 314.5 of this Act.

21          (ii-10) "Physician" (except when the context otherwise  
22          requires) means a person licensed to practice medicine in all  
23          of its branches.

24          (jj) "Poppy straw" means all parts, except the seeds, of  
25          the opium poppy, after mowing.

26          (kk) "Practitioner" means a physician licensed to practice

1 medicine in all its branches, dentist, optometrist, podiatric  
2 physician, veterinarian, scientific investigator, pharmacist,  
3 physician assistant, advanced practice registered nurse,  
4 licensed practical nurse, registered nurse, emergency medical  
5 services personnel, hospital, laboratory, or pharmacy, or  
6 other person licensed, registered, or otherwise lawfully  
7 permitted by the United States or this State to distribute,  
8 dispense, conduct research with respect to, administer or use  
9 in teaching or chemical analysis, a controlled substance in  
10 the course of professional practice or research.

11 (ll) "Pre-printed prescription" means a written  
12 prescription upon which the designated drug has been indicated  
13 prior to the time of issuance; the term does not mean a written  
14 prescription that is individually generated by machine or  
15 computer in the prescriber's office.

16 (mm) "Prescriber" means a physician licensed to practice  
17 medicine in all its branches, dentist, optometrist,  
18 prescribing psychologist licensed under Section 4.2 of the  
19 Clinical Psychologist Licensing Act with prescriptive  
20 authority delegated under Section 4.3 of the Clinical  
21 Psychologist Licensing Act, podiatric physician, or  
22 veterinarian who issues a prescription, a physician assistant  
23 who issues a prescription for a controlled substance in  
24 accordance with Section 303.05, a written delegation, and a  
25 written collaborative agreement required under Section 7.5 of  
26 the Physician Assistant Practice Act of 1987, an advanced

1 practice registered nurse with prescriptive authority  
2 delegated under Section 65-40 of the Nurse Practice Act and in  
3 accordance with Section 303.05, a written delegation, and a  
4 written collaborative agreement under Section 65-35 of the  
5 Nurse Practice Act, an advanced practice registered nurse  
6 certified as a nurse practitioner, nurse midwife, or clinical  
7 nurse specialist who has been granted authority to prescribe  
8 by a hospital affiliate in accordance with Section 65-45 of  
9 the Nurse Practice Act and in accordance with Section 303.05,  
10 or an advanced practice registered nurse certified as a nurse  
11 practitioner, nurse midwife, or clinical nurse specialist who  
12 has full practice authority pursuant to Section 65-43 of the  
13 Nurse Practice Act.

14 (nn) "Prescription" means a written, facsimile, or oral  
15 order, or an electronic order that complies with applicable  
16 federal requirements, of a physician licensed to practice  
17 medicine in all its branches, dentist, podiatric physician or  
18 veterinarian for any controlled substance, of an optometrist  
19 in accordance with Section 15.1 of the Illinois Optometric  
20 Practice Act of 1987, of a prescribing psychologist licensed  
21 under Section 4.2 of the Clinical Psychologist Licensing Act  
22 with prescriptive authority delegated under Section 4.3 of the  
23 Clinical Psychologist Licensing Act, of a physician assistant  
24 for a controlled substance in accordance with Section 303.05,  
25 a written delegation, and a written collaborative agreement  
26 required under Section 7.5 of the Physician Assistant Practice

1 Act of 1987, of an advanced practice registered nurse with  
2 prescriptive authority delegated under Section 65-40 of the  
3 Nurse Practice Act who issues a prescription for a controlled  
4 substance in accordance with Section 303.05, a written  
5 delegation, and a written collaborative agreement under  
6 Section 65-35 of the Nurse Practice Act, of an advanced  
7 practice registered nurse certified as a nurse practitioner,  
8 nurse midwife, or clinical nurse specialist who has been  
9 granted authority to prescribe by a hospital affiliate in  
10 accordance with Section 65-45 of the Nurse Practice Act and in  
11 accordance with Section 303.05 when required by law, or of an  
12 advanced practice registered nurse certified as a nurse  
13 practitioner, nurse midwife, or clinical nurse specialist who  
14 has full practice authority pursuant to Section 65-43 of the  
15 Nurse Practice Act.

16 (nn-5) "Prescription Information Library" (PIL) means an  
17 electronic library that contains reported controlled substance  
18 data.

19 (nn-10) "Prescription Monitoring Program" (PMP) means the  
20 entity that collects, tracks, and stores reported data on  
21 controlled substances and select drugs pursuant to Section  
22 316.

23 (oo) "Production" or "produce" means manufacture,  
24 planting, cultivating, growing, or harvesting of a controlled  
25 substance other than methamphetamine.

26 (pp) "Registrant" means every person who is required to



1 register under Section 302 of this Act.

2 (qq) "Registry number" means the number assigned to each  
3 person authorized to handle controlled substances under the  
4 laws of the United States and of this State.

5 (qq-5) "Secretary" means, as the context requires, either  
6 the Secretary of the Department or the Secretary of the  
7 Department of Financial and Professional Regulation, and the  
8 Secretary's designated agents.

9 (rr) "State" includes the State of Illinois and any state,  
10 district, commonwealth, territory, insular possession thereof,  
11 and any area subject to the legal authority of the United  
12 States of America.

13 (rr-5) "Stimulant" means any drug that (i) causes an  
14 overall excitation of central nervous system functions, (ii)  
15 causes impaired consciousness and awareness, and (iii) can be  
16 habit-forming or lead to a substance abuse problem, including,  
17 but not limited to, amphetamines and their analogs,  
18 methylphenidate and its analogs, cocaine, and phencyclidine  
19 and its analogs.

20 (rr-10) "Synthetic drug" includes, but is not limited to,  
21 any synthetic cannabinoids or piperazines or any synthetic  
22 cathinones as provided for in Schedule I.

23 (ss) "Ultimate user" means a person who lawfully possesses  
24 a controlled substance for his or her own use or for the use of  
25 a member of his or her household or for administering to an  
26 animal owned by him or her or by a member of his or her

1 household.

2 (Source: P.A. 101-666, eff. 1-1-22; 102-389, eff. 1-1-22;  
3 102-538, eff. 8-20-21; 102-813, eff. 5-13-22.)

4 (Text of Section after amendment by P.A. 103-881)

5 Sec. 102. Definitions. As used in this Act, unless the  
6 context otherwise requires:

7 (a) "Person with a substance use disorder" means any  
8 person who has a substance use disorder diagnosis defined as a  
9 spectrum of persistent and recurring problematic behavior that  
10 encompasses 10 separate classes of drugs: alcohol; caffeine;  
11 cannabis; hallucinogens; inhalants; opioids; sedatives,  
12 hypnotics and anxiolytics; stimulants; and tobacco; and other  
13 unknown substances leading to clinically significant  
14 impairment or distress.

15 (b) "Administer" means the direct application of a  
16 controlled substance, whether by injection, inhalation,  
17 ingestion, or any other means, to the body of a patient,  
18 research subject, or animal (as defined by the Humane  
19 Euthanasia in Animal Shelters Act) by:

20 (1) a practitioner (or, in his or her presence, by his  
21 or her authorized agent),

22 (2) the patient or research subject pursuant to an  
23 order, or

24 (3) a euthanasia technician as defined by the Humane  
25 Euthanasia in Animal Shelters Act.

1 (c) "Agent" means an authorized person who acts on behalf  
2 of or at the direction of a manufacturer, distributor,  
3 dispenser, prescriber, or practitioner. It does not include a  
4 common or contract carrier, public warehouseman or employee of  
5 the carrier or warehouseman.

6 (c-1) "Anabolic Steroids" means any drug or hormonal  
7 substance, chemically and pharmacologically related to  
8 testosterone (other than estrogens, progestins,  
9 corticosteroids, and dehydroepiandrosterone), and includes:

- 10 (i) 3[beta],17-dihydroxy-5a-androstane,  
11 (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane,  
12 (iii) 5[alpha]-androstane-3,17-dione,  
13 (iv) 1-androstenediol (3[beta],  
14 17[beta]-dihydroxy-5[alpha]-androst-1-ene),  
15 (v) 1-androstenediol (3[alpha],  
16 17[beta]-dihydroxy-5[alpha]-androst-1-ene),  
17 (vi) 4-androstenediol  
18 (3[beta],17[beta]-dihydroxy-androst-4-ene),  
19 (vii) 5-androstenediol  
20 (3[beta],17[beta]-dihydroxy-androst-5-ene),  
21 (viii) 1-androstenedione  
22 ([5alpha]-androst-1-en-3,17-dione),  
23 (ix) 4-androstenedione  
24 (androst-4-en-3,17-dione),  
25 (x) 5-androstenedione  
26 (androst-5-en-3,17-dione),

(xi) bolasterone (7[alpha],17a-dimethyl-17[beta]-hydroxyandrost-4-en-3-one),

(xii) boldenone (17[beta]-hydroxyandrost-1,4,-diene-3-one),

(xiii) boldione (androsta-1,4-diene-3,17-dione),

(xiv) calusterone (7[beta],17[alpha]-dimethyl-17[beta]-hydroxyandrost-4-en-3-one),

(xv) clostebol (4-chloro-17[beta]-hydroxyandrost-4-en-3-one),

(xvi) dehydrochloromethyltestosterone (4-chloro-17[beta]-hydroxy-17[alpha]-methyl-androst-1,4-dien-3-one),

(xvii) desoxymethyltestosterone (17[alpha]-methyl-5[alpha]-androst-2-en-17[beta]-ol) (a.k.a., madol),

(xviii) [delta]1-dihydrotestosterone (a.k.a. '1-testosterone') (17[beta]-hydroxy-5[alpha]-androst-1-en-3-one),

(xix) 4-dihydrotestosterone (17[beta]-hydroxy-androstan-3-one),

(xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl-5[alpha]-androstan-3-one),

(xxi) ethylestrenol (17[alpha]-ethyl-17[beta]-hydroxyestr-4-ene),

(xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl-

1 1[beta],17[beta]-dihydroxyandrost-4-en-3-one),  
2 (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha],  
3 17[beta]-dihydroxyandrost-1,4-dien-3-one),  
4 (xxiv) furazabol (17[alpha]-methyl-17[beta]-  
5 hydroxyandrostano[2,3-c]-furazan),  
6 (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one,  
7 (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy-  
8 androst-4-en-3-one),  
9 (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]-  
10 dihydroxy-estr-4-en-3-one),  
11 (xxviii) mestanolone (17[alpha]-methyl-17[beta]-  
12 hydroxy-5-androstan-3-one),  
13 (xxix) mesterolone (1amethyl-17[beta]-hydroxy-  
14 [5a]-androstan-3-one),  
15 (xxx) methandienone (17[alpha]-methyl-17[beta]-  
16 hydroxyandrost-1,4-dien-3-one),  
17 (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]-  
18 dihydroxyandrost-5-ene),  
19 (xxxii) methenolone (1-methyl-17[beta]-hydroxy-  
20 5[alpha]-androst-1-en-3-one),  
21 (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]-  
22 dihydroxy-5a-androstane,  
23 (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy  
24 -5a-androstane,  
25 (xxxv) 17[alpha]-methyl-3[beta],17[beta]-  
26 dihydroxyandrost-4-ene),

(xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]-methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one),  
(xxxvii) methyldienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9(10)-dien-3-one),  
(xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]-hydroxyestra-4,9-11-trien-3-one),  
(xxxix) methyltestosterone (17[alpha]-methyl-17[beta]-hydroxyandrost-4-en-3-one),  
(xl) mibolerone (7[alpha],17a-dimethyl-17[beta]-hydroxyestr-4-en-3-one),  
(xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]-androst-1-en-3-one) (a.k.a. '17-[alpha]-methyl-1-testosterone'),  
(xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one),  
(xliii) 19-nor-4-androstenediol (3[beta], 17[beta]-dihydroxyestr-4-ene),  
(xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]-dihydroxyestr-4-ene),  
(xlv) 19-nor-5-androstenediol (3[beta], 17[beta]-dihydroxyestr-5-ene),  
(xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]-dihydroxyestr-5-ene),  
(xlvii) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-diene-3,17-dione),  
(xlviii) 19-nor-4-androstenedione (estr-4-

1           en-3,17-dione),  
2       (xlix) 19-nor-5-androstenedione (estr-5-  
3           en-3,17-dione),  
4       (l) norbolethone (13[beta], 17a-diethyl-17[beta]-  
5           hydroxygon-4-en-3-one),  
6       (li) norclostebol (4-chloro-17[beta]-  
7           hydroxyestr-4-en-3-one),  
8       (lii) norethandrolone (17[alpha]-ethyl-17[beta]-  
9           hydroxyestr-4-en-3-one),  
10      (liii) normethandrolone (17[alpha]-methyl-17[beta]-  
11           hydroxyestr-4-en-3-one),  
12      (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy-  
13           2-oxa-5[alpha]-androstan-3-one),  
14      (lv) oxymesterone (17[alpha]-methyl-4,17[beta]-  
15           dihydroxyandrost-4-en-3-one),  
16      (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene-  
17           17[beta]-hydroxy-(5[alpha]-androstan-3-one),  
18      (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy-  
19           (5[alpha]-androst-2-eno[3,2-c]-pyrazole),  
20      (lviii) stenbolone (17[beta]-hydroxy-2-methyl-  
21           (5[alpha]-androst-1-en-3-one),  
22      (lix) testolactone (13-hydroxy-3-oxo-13,17-  
23           secoandrosta-1,4-dien-17-oic  
24           acid lactone),  
25      (lx) testosterone (17[beta]-hydroxyandrost-  
26           4-en-3-one),

(lxi) tetrahydrogestrinone (13[beta], 17[alpha]-  
diethyl-17[beta]-hydroxygon-  
4,9,11-trien-3-one),  
(lxii) trenbolone (17[beta]-hydroxyestr-4,9,  
11-trien-3-one).

Any person who is otherwise lawfully in possession of an anabolic steroid, or who otherwise lawfully manufactures, distributes, dispenses, delivers, or possesses with intent to deliver an anabolic steroid, which anabolic steroid is expressly intended for and lawfully allowed to be administered through implants to livestock or other nonhuman species, and which is approved by the Secretary of Health and Human Services for such administration, and which the person intends to administer or have administered through such implants, shall not be considered to be in unauthorized possession or to unlawfully manufacture, distribute, dispense, deliver, or possess with intent to deliver such anabolic steroid for purposes of this Act.

(d) "Administration" means the Drug Enforcement Administration, United States Department of Justice, or its successor agency.

(d-5) "Clinical Director, Prescription Monitoring Program" means a Department of Human Services administrative employee licensed to either prescribe or dispense controlled substances who shall run the clinical aspects of the Department of Human Services Prescription Monitoring Program and its Prescription



1 Information Library.

2 (d-10) "Compounding" means the preparation and mixing of  
3 components, excluding flavorings, (1) as the result of a  
4 prescriber's prescription drug order or initiative based on  
5 the prescriber-patient-pharmacist relationship in the course  
6 of professional practice or (2) for the purpose of, or  
7 incident to, research, teaching, or chemical analysis and not  
8 for sale or dispensing. "Compounding" includes the preparation  
9 of drugs or devices in anticipation of receiving prescription  
10 drug orders based on routine, regularly observed dispensing  
11 patterns. Commercially available products may be compounded  
12 for dispensing to individual patients only if both of the  
13 following conditions are met: (i) the commercial product is  
14 not reasonably available from normal distribution channels in  
15 a timely manner to meet the patient's needs and (ii) the  
16 prescribing practitioner has requested that the drug be  
17 compounded.

18 (e) "Control" means to add a drug or other substance, or  
19 immediate precursor, to a Schedule whether by transfer from  
20 another Schedule or otherwise.

21 (f) "Controlled Substance" means (i) a drug, substance,  
22 immediate precursor, or synthetic drug in the Schedules of  
23 Article II of this Act or (ii) a drug or other substance, or  
24 immediate precursor, designated as a controlled substance by  
25 the Department through administrative rule. The term does not  
26 include distilled spirits, wine, malt beverages, or tobacco,

1 as those terms are defined or used in the Liquor Control Act of  
2 1934 and the Tobacco Products Tax Act of 1995.

3 (f-5) "Controlled substance analog" means a substance:

4 (1) the chemical structure of which is substantially  
5 similar to the chemical structure of a controlled  
6 substance in Schedule I or II;

7 (2) which has a stimulant, depressant, or  
8 hallucinogenic effect on the central nervous system that  
9 is substantially similar to or greater than the stimulant,  
10 depressant, or hallucinogenic effect on the central  
11 nervous system of a controlled substance in Schedule I or  
12 II; or

13 (3) with respect to a particular person, which such  
14 person represents or intends to have a stimulant,  
15 depressant, or hallucinogenic effect on the central  
16 nervous system that is substantially similar to or greater  
17 than the stimulant, depressant, or hallucinogenic effect  
18 on the central nervous system of a controlled substance in  
19 Schedule I or II.

20 (g) "Counterfeit substance" means a controlled substance,  
21 which, or the container or labeling of which, without  
22 authorization bears the trademark, trade name, or other  
23 identifying mark, imprint, number or device, or any likeness  
24 thereof, of a manufacturer, distributor, or dispenser other  
25 than the person who in fact manufactured, distributed, or  
26 dispensed the substance.

1           (h) "Deliver" or "delivery" means the actual, constructive  
2           or attempted transfer of possession of a controlled substance,  
3           with or without consideration, whether or not there is an  
4           agency relationship. "Deliver" or "delivery" does not include  
5           the donation of drugs to the extent permitted under the  
6           Illinois Drug Reuse Opportunity Program Act.

7           (i) "Department" means the Illinois Department of Human  
8           Services (as successor to the Department of Alcoholism and  
9           Substance Abuse) or its successor agency.

10          (j) (Blank).

11          (k) "Department of Corrections" means the Department of  
12          Corrections of the State of Illinois or its successor agency.

13          (l) "Department of Financial and Professional Regulation"  
14          means the Department of Financial and Professional Regulation  
15          of the State of Illinois or its successor agency.

16          (m) "Depressant" means any drug that (i) causes an overall  
17          depression of central nervous system functions, (ii) causes  
18          impaired consciousness and awareness, and (iii) can be  
19          habit-forming or lead to a substance misuse or substance use  
20          disorder, including, but not limited to, alcohol, cannabis and  
21          its active principles and their analogs, benzodiazepines and  
22          their analogs, barbiturates and their analogs, opioids  
23          (natural and synthetic) and their analogs, and chloral hydrate  
24          and similar sedative hypnotics.

25          (n) (Blank).

26          (o) "Director" means the Director of the Illinois State

1 Police or his or her designated agents.

2 (p) "Dispense" means to deliver a controlled substance to  
3 an ultimate user or research subject by or pursuant to the  
4 lawful order of a prescriber, including the prescribing,  
5 administering, packaging, labeling, or compounding necessary  
6 to prepare the substance for that delivery.

7 (q) "Dispenser" means a practitioner who dispenses.

8 (r) "Distribute" means to deliver, other than by  
9 administering or dispensing, a controlled substance.

10 (s) "Distributor" means a person who distributes.

11 (t) "Drug" means (1) substances recognized as drugs in the  
12 official United States Pharmacopoeia, Official Homeopathic  
13 Pharmacopoeia of the United States, or official National  
14 Formulary, or any supplement to any of them; (2) substances  
15 intended for use in diagnosis, cure, mitigation, treatment, or  
16 prevention of disease in man or animals; (3) substances (other  
17 than food) intended to affect the structure of any function of  
18 the body of man or animals and (4) substances intended for use  
19 as a component of any article specified in clause (1), (2), or  
20 (3) of this subsection. It does not include devices or their  
21 components, parts, or accessories.

22 (t-3) "Electronic health record" or "EHR" means an  
23 electronic record of health-related information on an  
24 individual that is created, gathered, managed, and consulted  
25 by authorized health care clinicians and staff.

26 (t-3.5) "Electronic health record system" or "EHR system"

1 means any computer-based system or combination of federally  
2 certified Health IT Modules (defined at 42 CFR 170.102 or its  
3 successor) used as a repository for electronic health records  
4 and accessed or updated by a prescriber or authorized  
5 surrogate in the ordinary course of his or her medical  
6 practice. For purposes of connecting to the Prescription  
7 Information Library maintained by the Bureau of Pharmacy and  
8 Clinical Support Systems or its successor, an EHR system may  
9 connect to the Prescription Information Library directly or  
10 through all or part of a computer program or system that is a  
11 federally certified Health IT Module maintained by a third  
12 party and used by the EHR system to secure access to the  
13 database.

14 (t-4) "Emergency medical services personnel" has the  
15 meaning ascribed to it in the Emergency Medical Services (EMS)  
16 Systems Act.

17 (t-5) "Euthanasia agency" means an entity certified by the  
18 Department of Financial and Professional Regulation for the  
19 purpose of animal euthanasia that holds an animal control  
20 facility license or animal shelter license under the Animal  
21 Welfare Act. A euthanasia agency is authorized to purchase,  
22 store, possess, and utilize Schedule II nonnarcotic and  
23 Schedule III nonnarcotic drugs for the sole purpose of animal  
24 euthanasia.

25 (t-10) "Euthanasia drugs" means Schedule II or Schedule  
26 III substances (nonnarcotic controlled substances) that are

1 used by a euthanasia agency for the purpose of animal  
2 euthanasia.

3 (u) "Good faith" means the prescribing or dispensing of a  
4 controlled substance by a practitioner in the regular course  
5 of professional treatment to or for any person who is under his  
6 or her treatment for a pathology or condition other than that  
7 individual's physical or psychological dependence upon a  
8 controlled substance, except as provided herein: and  
9 application of the term to a pharmacist shall mean the  
10 dispensing of a controlled substance pursuant to the  
11 prescriber's order which in the professional judgment of the  
12 pharmacist is lawful. The pharmacist shall be guided by  
13 accepted professional standards, including, but not limited  
14 to, the following, in making the judgment:

15 (1) lack of consistency of prescriber-patient  
16 relationship,

17 (2) frequency of prescriptions for same drug by one  
18 prescriber for large numbers of patients,

19 (3) quantities beyond those normally prescribed,

20 (4) unusual dosages (recognizing that there may be  
21 clinical circumstances where more or less than the usual  
22 dose may be used legitimately),

23 (5) unusual geographic distances between patient,  
24 pharmacist and prescriber,

25 (6) consistent prescribing of habit-forming drugs.

26 (u-0.5) "Hallucinogen" means a drug that causes markedly

1 altered sensory perception leading to hallucinations of any  
2 type.

3 (u-1) "Home infusion services" means services provided by  
4 a pharmacy in compounding solutions for direct administration  
5 to a patient in a private residence, long-term care facility,  
6 or hospice setting by means of parenteral, intravenous,  
7 intramuscular, subcutaneous, or intraspinal infusion.

8 (u-5) "Illinois State Police" means the Illinois State  
9 Police or its successor agency.

10 (v) "Immediate precursor" means a substance:

11 (1) which the Department has found to be and by rule  
12 designated as being a principal compound used, or produced  
13 primarily for use, in the manufacture of a controlled  
14 substance;

15 (2) which is an immediate chemical intermediary used  
16 or likely to be used in the manufacture of such controlled  
17 substance; and

18 (3) the control of which is necessary to prevent,  
19 curtail or limit the manufacture of such controlled  
20 substance.

21 (w) "Instructional activities" means the acts of teaching,  
22 educating or instructing by practitioners using controlled  
23 substances within educational facilities approved by the State  
24 Board of Education or its successor agency.

25 (w-1) "Isomer" means optical isomer, unless specifically  
26 detailed in this Act.

1           (x) "Local authorities" means a duly organized State,  
2 County or Municipal peace unit or police force.

3           (y) "Look-alike substance" means a substance, other than a  
4 controlled substance which (1) by overall dosage unit  
5 appearance, including shape, color, size, markings or lack  
6 thereof, taste, consistency, or any other identifying physical  
7 characteristic of the substance, would lead a reasonable  
8 person to believe that the substance is a controlled  
9 substance, or (2) is expressly or impliedly represented to be  
10 a controlled substance or is distributed under circumstances  
11 which would lead a reasonable person to believe that the  
12 substance is a controlled substance. For the purpose of  
13 determining whether the representations made or the  
14 circumstances of the distribution would lead a reasonable  
15 person to believe the substance to be a controlled substance  
16 under this clause (2) of subsection (y), the court or other  
17 authority may consider the following factors in addition to  
18 any other factor that may be relevant:

19           (a) statements made by the owner or person in control  
20 of the substance concerning its nature, use or effect;

21           (b) statements made to the buyer or recipient that the  
22 substance may be resold for profit;

23           (c) whether the substance is packaged in a manner  
24 normally used for the illegal distribution of controlled  
25 substances;

26           (d) whether the distribution or attempted distribution



1 included an exchange of or demand for money or other  
2 property as consideration, and whether the amount of the  
3 consideration was substantially greater than the  
4 reasonable retail market value of the substance.

5 Clause (1) of this subsection (y) shall not apply to a  
6 noncontrolled substance in its finished dosage form that was  
7 initially introduced into commerce prior to the initial  
8 introduction into commerce of a controlled substance in its  
9 finished dosage form which it may substantially resemble.

10 Nothing in this subsection (y) prohibits the dispensing or  
11 distributing of noncontrolled substances by persons authorized  
12 to dispense and distribute controlled substances under this  
13 Act, provided that such action would be deemed to be carried  
14 out in good faith under subsection (u) if the substances  
15 involved were controlled substances.

16 Nothing in this subsection (y) or in this Act prohibits  
17 the manufacture, preparation, propagation, compounding,  
18 processing, packaging, advertising or distribution of a drug  
19 or drugs by any person registered pursuant to Section 510 of  
20 the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).

21 (y-1) "Mail-order pharmacy" means a pharmacy that is  
22 located in a state of the United States that delivers,  
23 dispenses or distributes, through the United States Postal  
24 Service or other common carrier, to Illinois residents, any  
25 substance which requires a prescription.

26 (z) "Manufacture" means the production, preparation,

1 propagation, compounding, conversion or processing of a  
2 controlled substance other than methamphetamine, either  
3 directly or indirectly, by extraction from substances of  
4 natural origin, or independently by means of chemical  
5 synthesis, or by a combination of extraction and chemical  
6 synthesis, and includes any packaging or repackaging of the  
7 substance or labeling of its container, except that this term  
8 does not include:

9 (1) by an ultimate user, the preparation or  
10 compounding of a controlled substance for his or her own  
11 use;

12 (2) by a practitioner, or his or her authorized agent  
13 under his or her supervision, the preparation,  
14 compounding, packaging, or labeling of a controlled  
15 substance:

16 (a) as an incident to his or her administering or  
17 dispensing of a controlled substance in the course of  
18 his or her professional practice; or

19 (b) as an incident to lawful research, teaching or  
20 chemical analysis and not for sale; or

21 (3) the packaging, repackaging, or labeling of drugs  
22 only to the extent permitted under the Illinois Drug Reuse  
23 Opportunity Program Act.

24 (z-1) (Blank).

25 (z-5) "Medication shopping" means the conduct prohibited  
26 under subsection (a) of Section 314.5 of this Act.

1           (z-10) "Mid-level practitioner" means (i) a physician  
2 assistant who has been delegated authority to prescribe  
3 through a written delegation of authority by a physician  
4 licensed to practice medicine in all of its branches, in  
5 accordance with Section 7.5 of the Physician Assistant  
6 Practice Act of 1987, (ii) an advanced practice registered  
7 nurse who has been delegated authority to prescribe through a  
8 written delegation of authority by a physician licensed to  
9 practice medicine in all of its branches or by a podiatric  
10 physician, in accordance with Section 65-40 of the Nurse  
11 Practice Act, (iii) an advanced practice registered nurse  
12 certified as a nurse practitioner, nurse midwife, or clinical  
13 nurse specialist who has been granted authority to prescribe  
14 by a hospital affiliate in accordance with Section 65-45 of  
15 the Nurse Practice Act, (iv) an animal euthanasia agency, or  
16 (v) a prescribing psychologist.

17           (aa) "Narcotic drug" means any of the following, whether  
18 produced directly or indirectly by extraction from substances  
19 of vegetable origin, or independently by means of chemical  
20 synthesis, or by a combination of extraction and chemical  
21 synthesis:

22               (1) opium, opiates, derivatives of opium and opiates,  
23 including their isomers, esters, ethers, salts, and salts  
24 of isomers, esters, and ethers, whenever the existence of  
25 such isomers, esters, ethers, and salts is possible within  
26 the specific chemical designation; however the term

1 "narcotic drug" does not include the isoquinoline  
2 alkaloids of opium;

3 (2) (blank);

4 (3) opium poppy and poppy straw;

5 (4) coca leaves, except coca leaves and extracts of  
6 coca leaves from which substantially all of the cocaine  
7 and ecgonine, and their isomers, derivatives and salts,  
8 have been removed;

9 (5) cocaine, its salts, optical and geometric isomers,  
10 and salts of isomers;

11 (6) ecgonine, its derivatives, their salts, isomers,  
12 and salts of isomers;

13 (7) any compound, mixture, or preparation which  
14 contains any quantity of any of the substances referred to  
15 in subparagraphs (1) through (6).

16 (bb) "Nurse" means a registered nurse licensed under the  
17 Nurse Practice Act.

18 (cc) (Blank).

19 (dd) "Opiate" means a drug derived from or related to  
20 opium.

21 (ee) "Opium poppy" means the plant of the species *Papaver*  
22 *somniferum* L., except its seeds.

23 (ee-5) "Oral dosage" means a tablet, capsule, elixir, or  
24 solution or other liquid form of medication intended for  
25 administration by mouth, but the term does not include a form  
26 of medication intended for buccal, sublingual, or transmucosal

1 administration.

2 (ff) "Parole and Pardon Board" means the Parole and Pardon  
3 Board of the State of Illinois or its successor agency.

4 (gg) "Person" means any individual, corporation,  
5 mail-order pharmacy, government or governmental subdivision or  
6 agency, business trust, estate, trust, partnership or  
7 association, or any other entity.

8 (hh) "Pharmacist" means any person who holds a license or  
9 certificate of registration as a registered pharmacist, a  
10 local registered pharmacist or a registered assistant  
11 pharmacist under the Pharmacy Practice Act.

12 (ii) "Pharmacy" means any store, ship or other place in  
13 which pharmacy is authorized to be practiced under the  
14 Pharmacy Practice Act.

15 (ii-5) "Pharmacy shopping" means the conduct prohibited  
16 under subsection (b) of Section 314.5 of this Act.

17 (ii-10) "Physician" (except when the context otherwise  
18 requires) means a person licensed to practice medicine in all  
19 of its branches.

20 (jj) "Poppy straw" means all parts, except the seeds, of  
21 the opium poppy, after mowing.

22 (kk) "Practitioner" means a physician licensed to practice  
23 medicine in all its branches, dentist, optometrist, podiatric  
24 physician, veterinarian, scientific investigator, pharmacist,  
25 physician assistant, advanced practice registered nurse,  
26 licensed practical nurse, registered nurse, emergency medical

1 services personnel, hospital, laboratory, or pharmacy, or  
2 other person licensed, registered, or otherwise lawfully  
3 permitted by the United States or this State to distribute,  
4 dispense, conduct research with respect to, administer or use  
5 in teaching or chemical analysis, a controlled substance in  
6 the course of professional practice or research.

7 (ll) "Pre-printed prescription" means a written  
8 prescription upon which the designated drug has been indicated  
9 prior to the time of issuance; the term does not mean a written  
10 prescription that is individually generated by machine or  
11 computer in the prescriber's office.

12 (mm) "Prescriber" means a physician licensed to practice  
13 medicine in all its branches, dentist, optometrist,  
14 prescribing psychologist licensed under Section 4.2 of the  
15 Clinical Psychologist Licensing Act with prescriptive  
16 authority delegated under Section 4.3 of the Clinical  
17 Psychologist Licensing Act, podiatric physician, or  
18 veterinarian who issues a prescription, a physician assistant  
19 who issues a prescription for a controlled substance in  
20 accordance with Section 303.05, a written delegation, and a  
21 written collaborative agreement required under Section 7.5 of  
22 the Physician Assistant Practice Act of 1987, an advanced  
23 practice registered nurse with prescriptive authority  
24 delegated under Section 65-40 of the Nurse Practice Act and in  
25 accordance with Section 303.05, a written delegation, and a  
26 written collaborative agreement under Section 65-35 of the

1 Nurse Practice Act, an advanced practice registered nurse  
2 certified as a nurse practitioner, nurse midwife, or clinical  
3 nurse specialist who has been granted authority to prescribe  
4 by a hospital affiliate in accordance with Section 65-45 of  
5 the Nurse Practice Act and in accordance with Section 303.05,  
6 or an advanced practice registered nurse certified as a nurse  
7 practitioner, nurse midwife, or clinical nurse specialist who  
8 has full practice authority pursuant to Section 65-43 of the  
9 Nurse Practice Act.

10 (nn) "Prescription" means a written, facsimile, or oral  
11 order, or an electronic order that complies with applicable  
12 federal requirements, of a physician licensed to practice  
13 medicine in all its branches, dentist, podiatric physician or  
14 veterinarian for any controlled substance, of an optometrist  
15 in accordance with Section 15.1 of the Illinois Optometric  
16 Practice Act of 1987, of a prescribing psychologist licensed  
17 under Section 4.2 of the Clinical Psychologist Licensing Act  
18 with prescriptive authority delegated under Section 4.3 of the  
19 Clinical Psychologist Licensing Act, of a physician assistant  
20 for a controlled substance in accordance with Section 303.05,  
21 a written delegation, and a written collaborative agreement  
22 required under Section 7.5 of the Physician Assistant Practice  
23 Act of 1987, of an advanced practice registered nurse with  
24 prescriptive authority delegated under Section 65-40 of the  
25 Nurse Practice Act who issues a prescription for a controlled  
26 substance in accordance with Section 303.05, a written

1 delegation, and a written collaborative agreement under  
2 Section 65-35 of the Nurse Practice Act, of an advanced  
3 practice registered nurse certified as a nurse practitioner,  
4 nurse midwife, or clinical nurse specialist who has been  
5 granted authority to prescribe by a hospital affiliate in  
6 accordance with Section 65-45 of the Nurse Practice Act and in  
7 accordance with Section 303.05 when required by law, or of an  
8 advanced practice registered nurse certified as a nurse  
9 practitioner, nurse midwife, or clinical nurse specialist who  
10 has full practice authority pursuant to Section 65-43 of the  
11 Nurse Practice Act.

12 (nn-5) "Prescription Information Library" (PIL) means an  
13 electronic library that contains reported controlled substance  
14 data.

15 (nn-10) "Prescription Monitoring Program" (PMP) means the  
16 entity that collects, tracks, and stores reported data on  
17 controlled substances and select drugs pursuant to Section  
18 316.

19 (oo) "Production" or "produce" means manufacture,  
20 planting, cultivating, growing, or harvesting of a controlled  
21 substance other than methamphetamine.

22 (pp) "Registrant" means every person who is required to  
23 register under Section 302 of this Act.

24 (qq) "Registry number" means the number assigned to each  
25 person authorized to handle controlled substances under the  
26 laws of the United States and of this State.



1 (qq-5) "Secretary" means, as the context requires, either  
2 the Secretary of the Department or the Secretary of the  
3 Department of Financial and Professional Regulation, and the  
4 Secretary's designated agents.

5 (rr) "State" includes the State of Illinois and any state,  
6 district, commonwealth, territory, insular possession thereof,  
7 and any area subject to the legal authority of the United  
8 States of America.

9 (rr-5) "Stimulant" means any drug that (i) causes an  
10 overall excitation of central nervous system functions, (ii)  
11 causes impaired consciousness and awareness, and (iii) can be  
12 habit-forming or lead to a substance use disorder, including,  
13 but not limited to, amphetamines and their analogs,  
14 methylphenidate and its analogs, cocaine, and phencyclidine  
15 and its analogs.

16 (rr-10) "Synthetic drug" includes, but is not limited to,  
17 any synthetic cannabinoids or piperazines or any synthetic  
18 cathinones as provided for in Schedule I.

19 (ss) "Ultimate user" means a person who lawfully possesses  
20 a controlled substance for his or her own use or for the use of  
21 a member of his or her household or for administering to an  
22 animal owned by him or her or by a member of his or her  
23 household.

24 (Source: P.A. 102-389, eff. 1-1-22; 102-538, eff. 8-20-21;  
25 102-813, eff. 5-13-22; 103-881, eff. 1-1-25.)

(720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)

Sec. 204. (a) The controlled substances listed in this Section are included in Schedule I.

(b) Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation:

(1) Acetylmethadol;

(1.1) (Blank); ~~Acetyl-alpha-methylfentanyl~~

~~(N-[1-(1-methyl-2-phenethyl)-~~

~~4-piperidinyl]-N-phenylacetamide);~~

(2) Allylprodine;

(3) Alphacetylmethadol, except

levo-alphacetylmethadol (also known as levo-alpha-acetylmethadol, levomethadyl acetate, or LAAM);

(4) Alphameprodine;

(5) Alphamethadol;

(6) Alpha-methylfentanyl

(N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine;

(6.1) (Blank); ~~Alpha-methylthiofentanyl~~

~~(N-[1-methyl-2-(2-thienyl)ethyl-~~

~~4-piperidinyl]-N-phenylpropanamide);~~

1 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);  
2 (7.1) PEPAP  
3 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);  
4 (8) Benzethidine;  
5 (9) Betacetylmethadol;  
6 (9.1) (Blank); ~~Beta-hydroxyfentanyl~~  
7 ~~(N-[1-(2-hydroxy-2-phenethyl)-~~  
8 ~~4-piperidinyl]-N-phenylpropanamide);~~  
9 (10) Betameprodine;  
10 (11) Betamethadol;  
11 (12) Betaprodine;  
12 (12.1) Brorphine;  
13 (13) Clonitazene;  
14 (14) Dextromoramide;  
15 (15) Diampromide;  
16 (16) Diethylthiambutene;  
17 (17) Difenoxy;  
18 (18) Dimenoxadol;  
19 (19) Dimepheptanol;  
20 (20) Dimethylthiambutene;  
21 (21) Dioxaphetylbutyrate;  
22 (22) Dipipanone;  
23 (23) Ethylmethylthiambutene;  
24 (24) Etonitazene;  
25 (25) Etoxadine;  
26 (25.1) Flunitazene;

1 (26) Furethidine;  
2 (27) Hydroxpethidine;  
3 (27.1) Isotonitazene;  
4 (28) Ketobemidone;  
5 (29) Levomoramide;  
6 (30) Levophenacylmorphane;  
7 (31) (Blank); ~~3-Methylfentanyl~~  
8 ~~(N-[3-methyl-1-(2-phenylethyl)-~~  
9 ~~4-piperidyl]-N-phenylpropanamide);~~  
10 (31.1) (Blank); ~~3-Methylthiofentanyl~~  
11 ~~(N-[3-methyl-1-(2-thienyl)ethyl-~~  
12 ~~4-piperidinyl]-N-phenylpropanamide);~~  
13 (31.2) Metonitazene;  
14 (32) Morpheridine;  
15 (33) Noracymethadol;  
16 (34) Norlevorphanol;  
17 (35) Normethadone;  
18 (36) Norpipanone;  
19 (36.1) (Blank); ~~Para-fluorofentanyl~~  
20 ~~(N-(4-fluorophenyl)-N-[1-(2-phenethyl)-~~  
21 ~~4-piperidinyl]propanamide);~~  
22 (37) Phenadoxone;  
23 (38) Phenampromide;  
24 (39) Phenomorphan;  
25 (40) Phenoperidine;  
26 (41) Piritramide;

1 (42) Proheptazine;  
2 (43) Properidine;  
3 (44) Propiram;  
4 (45) Racemoramide;  
5 (45.1) (Blank); ~~Thiofentanyl~~  
6 ~~(N-phenyl-N-[1-(2-thienyl)ethyl-~~  
7 ~~4-piperidinyl]-propanamide);~~  
8 (46) Tilidine;  
9 (47) Trimeperidine;  
10 (48) (Blank); ~~Beta hydroxy 3-methylfentanyl (other~~  
11 ~~name:~~  
12 ~~N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-~~  
13 ~~N-phenylpropanamide);~~  
14 (49) (Blank); ~~Furanyl-fentanyl (FU-F);~~  
15 (50) (Blank); ~~Butyryl-fentanyl;~~  
16 (51) (Blank); ~~Valeryl-fentanyl;~~  
17 (52) (Blank); ~~Acetyl-fentanyl;~~  
18 (53) (Blank); ~~Beta hydroxy thiofentanyl;~~  
19 (54) 3,4-dichloro-N-[2-(  
20 (dimethylamino)cyclohexyl)-N-  
21 methylbenzamide (U-47700);  
22 (55) 4-chloro-N-[1-[2-(  
23 (4-nitrophenyl)ethyl]-2-piperidinylidene]-  
24 benzenesulfonamide (W-18);  
25 (56) 4-chloro-N-[1-(2-phenylethyl)-  
26 -2-piperidinylidene]-benzenesulfonamide (W-15);

1           (57) (Blank). ~~acrylfentanyl (acryloylfentanyl)~~.

2           (c) Unless specifically excepted or unless listed in  
3 another schedule, any of the following opium derivatives, its  
4 salts, isomers and salts of isomers, whenever the existence of  
5 such salts, isomers and salts of isomers is possible within  
6 the specific chemical designation:

- 7           (1) Acetorphine;  
8           (2) Acetyldihydrocodeine;  
9           (3) Benzylmorphine;  
10          (4) Codeine methylbromide;  
11          (5) Codeine-N-Oxide;  
12          (6) Cyprenorphine;  
13          (7) Desomorphine;  
14          (8) Diacetyldihydromorphine (Dihydroheroin);  
15          (9) Dihydromorphine;  
16          (10) Drotebanol;  
17          (11) Etorphine (except hydrochloride salt);  
18          (12) Heroin;  
19          (13) Hydromorphenol;  
20          (14) Methyldesorphine;  
21          (15) Methyldihydromorphine;  
22          (16) Morphine methylbromide;  
23          (17) Morphine methylsulfonate;  
24          (18) Morphine-N-Oxide;  
25          (19) Myrophine;  
26          (20) Nicocodeine;

(21) Nicomorphine;

(22) Normorphine;

(23) Pholcodine;

(24) Thebacon.

(d) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for the purposes of this paragraph only, the term "isomer" includes the optical, position and geometric isomers):

(1) 3,4-methylenedioxyamphetamine

(alpha-methyl, 3,4-methylenedioxyphenethylamine, methylenedioxyamphetamine, MDA);

(1.1) Alpha-ethyltryptamine

(some trade or other names: etryptamine; MONASE; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; a-ET; and AET);

(2) 3,4-methylenedioxymethamphetamine (MDMA);

(2.1) 3,4-methylenedioxy-N-ethylamphetamine

(also known as: N-ethyl-alpha-methyl-3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE, and MDEA);

(2.2) (Blank); ~~N-Benzylpiperazine (BZP);~~

1 (2.2-1) (Blank); ~~Trifluoromethylphenylpiperazine~~  
2 ~~(TFMPP);~~

3 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MDA);

4 (4) 3,4,5-trimethoxyamphetamine (TMA);

5 (5) (Blank);

6 (6) Diethyltryptamine (DET);

7 (7) Dimethyltryptamine (DMT);

8 (7.1) 5-Methoxy-diallyltryptamine;

9 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);

10 (9) Ibogaine (some trade and other names:  
11 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-  
12 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]  
13 indole; Tabernanthe iboga);

14 (10) Lysergic acid diethylamide;

15 (10.1) Salvinorin A;

16 (10.5) Salvia divinorum (meaning all parts of the  
17 plant presently classified botanically as Salvia  
18 divinorum, whether growing or not, the seeds thereof, any  
19 extract from any part of that plant, and every compound,  
20 manufacture, salts, isomers, and salts of isomers whenever  
21 the existence of such salts, isomers, and salts of isomers  
22 is possible within the specific chemical designation,  
23 derivative, mixture, or preparation of that plant, its  
24 seeds or extracts);

25 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);

26 (12) Peyote (meaning all parts of the plant presently



classified botanically as *Lophophora williamsii* Lemaire, whether growing or not, the seeds thereof, any extract from any part of that plant, and every compound, manufacture, salts, derivative, mixture, or preparation of that plant, its seeds or extracts);

(13) N-ethyl-3-piperidyl benzilate (JB 318);

(14) N-methyl-3-piperidyl benzilate;

(14.1) N-hydroxy-3,4-methylenedioxyamphetamine

(also known as N-hydroxy-alpha-methyl-

3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);

(15) Parahexyl; some trade or other names:

3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo (b,d) pyran; Synhexyl;

(16) Psilocybin;

(17) Psilocyn;

(18) Alpha-methyltryptamine (AMT);

(19) 2,5-dimethoxyamphetamine

(2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);

(20) 4-bromo-2,5-dimethoxyamphetamine

(4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;

4-bromo-2,5-DMA);

(20.1) 4-Bromo-2,5 dimethoxyphenethylamine.

Some trade or other names: 2-(4-bromo-

2,5-dimethoxyphenyl)-1-aminoethane;

alpha-desmethyl DOB, 2CB, Nexus;

(21) 4-methoxyamphetamine

1 (4-methoxy-alpha-methylphenethylamine;

2 paramethoxyamphetamine; PMA);

3 (22) (Blank);

4 (23) Ethylamine analog of phencyclidine.

5 Some trade or other names:

6 N-ethyl-1-phenylcyclohexylamine,

7 (1-phenylcyclohexyl) ethylamine,

8 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;

9 (24) Pyrrolidine analog of phencyclidine. Some trade  
10 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,  
11 PHP;

12 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;

13 (26) 2,5-dimethoxy-4-ethylamphetamine

14 (another name: DOET);

15 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine

16 (another name: TCPy);

17 (28) (Blank);

18 (29) Thiophene analog of phencyclidine (some trade  
19 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;

20 2-thienyl analog of phencyclidine; TCP; TCP);

21 (29.1) Benzothiophene analog of phencyclidine. Some  
22 trade or other names: BTCP or benocyclidine;

23 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);

24 (30) Bufotenine (some trade or other names:

25 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;

26 3-(2-dimethylaminoethyl)-5-indolol;

1 5-hydroxy-N,N-dimethyltryptamine;

2 N,N-dimethylserotonin; mappine);

3 (31) (Blank);

4 (32) (Blank);

5 (33) (Blank);

6 (34) (Blank);

7 (34.5) (Blank);

8 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-

9 (2-methyloctan-2-yl)-6a,7,

10 10,10a-tetrahydrobenzo[c]chromen-1-ol

11 Some trade or other names: HU-210;

12 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-

13 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-

14 tetrahydrobenzo[c]chromen-1-ol, its isomers,

15 salts, and salts of isomers; Some trade or other

16 names: HU-210, Dexanabinol;

17 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-

18 6,6-dimethyl-3-(2-methyloctan-2-yl)-

19 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol

20 Some trade or other names: HU-211;

21 (37) (Blank);

22 (38) (Blank);

23 (39) (Blank);

24 (40) (Blank);

25 (41) (Blank);

26 (42) (Blank); ~~Any compound structurally derived from~~

~~3-(1-naphthoyl)indole or  
1H-indol-3-yl-(1-naphthyl)methane by substitution at the  
nitrogen atom of the indole ring by alkyl, haloalkyl,  
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl whether or not further substituted  
in the indole ring to any extent, whether or not  
substituted in the naphthyl ring to any extent. Examples  
of this structural class include, but are not limited to,  
JWH 018, AM 2201, JWH 175, JWH 184, and JWH 185;~~

(43) (Blank); ~~Any compound structurally derived from  
3-(1-naphthoyl)pyrrole by substitution at the nitrogen  
atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,  
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
halide, 1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl, whether or not further substituted  
in the pyrrole ring to any extent, whether or not  
substituted in the naphthyl ring to any extent. Examples  
of this structural class include, but are not limited to,  
JWH 030, JWH 145, JWH 146, JWH 307, and JWH 368;~~

(44) (Blank); ~~Any compound structurally derived from  
1-(1-naphthylmethyl)indene by substitution at the  
3-position of the indene ring by alkyl, haloalkyl,  
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,  
alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl whether or not further substituted~~

1 ~~in the indene ring to any extent, whether or not~~  
2 ~~substituted in the naphthyl ring to any extent. Examples~~  
3 ~~of this structural class include, but are not limited to,~~  
4 ~~JWH-176;~~

5 (45) (Blank); ~~Any compound structurally derived from~~  
6 ~~3-phenylacetylindole by substitution at the nitrogen atom~~  
7 ~~of the indole ring with alkyl, haloalkyl, alkenyl,~~  
8 ~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl~~  
9 ~~halide, 1-(N-methyl-2-piperidinyl)methyl, or~~  
10 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~  
11 ~~in the indole ring to any extent, whether or not~~  
12 ~~substituted in the phenyl ring to any extent. Examples of~~  
13 ~~this structural class include, but are not limited to,~~  
14 ~~JWH-167, JWH-250, JWH-251, and RCS-8;~~

15 (46) (Blank); ~~Any compound structurally derived from~~  
16 ~~2-(3-hydroxycyclohexyl)phenol by substitution at the~~  
17 ~~5-position of the phenolic ring by alkyl, haloalkyl,~~  
18 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,~~  
19 ~~alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~  
20 ~~2-(4-morpholinyl)ethyl, whether or not substituted in the~~  
21 ~~cyclohexyl ring to any extent. Examples of this structural~~  
22 ~~class include, but are not limited to, CP-47, 497 and its~~  
23 ~~C8 homologue (cannabicyclohexanol);~~

24 (46.1) (Blank); ~~Any compound structurally derived from~~  
25 ~~3-(benzoyl)-indole with substitution at the nitrogen atom~~  
26 ~~of the indole ring by an alkyl, haloalkyl, alkenyl,~~

~~cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl  
halide, 1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl group whether or not further  
substituted in the indole ring to any extent and whether  
or not substituted in the phenyl ring to any extent.  
Examples of this structural class include, but are not  
limited to, AM 630, AM 2233, AM 694, Pravadolone (WIN  
48,098), and RCS 4;~~

(47) (Blank);

(48) (Blank);

(49) (Blank);

(50) (Blank);

(51) (Blank);

(52) (Blank);

(53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.

Some trade or other names: 2C-T-7;

(53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some  
trade or other names: 2C-E;

(53.2) 2,5-dimethoxy-4-methylphenethylamine. Some  
trade or other names: 2C-D;

(53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some  
trade or other names: 2C-C;

(53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade  
or other names: 2C-I;

(53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some  
trade or other names: 2C-T-2;

1 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.

2 Some trade or other names: 2C-T-4;

3 (53.7) 2,5-dimethoxyphenethylamine. Some trade or  
4 other names: 2C-H;

5 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some  
6 trade or other names: 2C-N;

7 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some  
8 trade or other names: 2C-P;

9 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.  
10 Some trade or other names: 2C-G;

11 (53.11) The N-(2-methoxybenzyl) derivative of any 2C  
12 phenethylamine referred to in subparagraphs (20.1), (53),  
13 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),  
14 (53.8), (53.9), and (53.10) including, but not limited to,  
15 25I-NBOMe and 25C-NBOMe;

16 (54) 5-Methoxy-N,N-diisopropyltryptamine;

17 (55) (Blank);

18 (56) (Blank);

19 (57) (Blank);

20 (58) (Blank);

21 (59) (Blank); ~~3-cyclopropylindole with substitution~~  
22 ~~at the nitrogen atom of the indole ring by alkyl,~~  
23 ~~haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,~~  
24 ~~aryl halide, alkyl aryl halide,~~  
25 ~~1-(N-methyl-2-piperidiny)methyl, or~~  
26 ~~2-(4-morpholinyl)ethyl, whether or not further substituted~~

~~on the indole ring to any extent, whether or not substituted on the cyclopropyl ring to any extent: including, but not limited to, XLR11, UR144, FUB-144,~~

(60) (Blank); ~~3-adamantoylindole with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1 (N methyl 2 piperidinyl)methyl, or 2 (4 morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent: including, but not limited to, AB-001;~~

(61) (Blank); ~~N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1 (N methyl 2 piperidinyl)methyl, or 2 (4 morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent: including, but not limited to, APICA/2NE-1, STS-135;~~

(62) (Blank); ~~N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1 (N methyl 2 piperidinyl)methyl, or 2 (4 morpholinyl)ethyl, whether or not further substituted~~



~~on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent: including, but not limited to, AKB48, 5F-AKB48,~~

(63) (Blank); ~~1H-indole-3-carboxylic acid 8-quinolinyl ester with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent, whether or not substituted on the quinoline ring to any extent: including, but not limited to, PB22, 5F-PB22, FUB-PB-22,~~

(64) (Blank); ~~3-(1-naphthoyl)indazole with substitution at the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the naphthyl ring to any extent: including, but not limited to, THJ-018, THJ-2201,~~

(65) (Blank); ~~2-(1-naphthoyl)benzimidazole with substitution at the nitrogen atom of the benzimidazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or~~

~~2-(4-morpholinyl)ethyl, whether or not further substituted on the benzimidazole ring to any extent, whether or not substituted on the naphthyl ring to any extent: including, but not limited to, FUBIMINA,~~

(66) (Blank); ~~N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including, but not limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA,~~

(67) (Blank); ~~N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including, but not limited to, ADB-PINACA, ADB-FUBINACA,~~

(68) (Blank); ~~N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-indole-3-carboxamide with substitution on the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted~~

~~on the indole ring to any extent: including, but not limited to, ADBICA, 5F ADBICA;~~

(69) (Blank); ~~N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-3-carboxamide with substitution on the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent: including, but not limited to, ABICA, 5F ABICA;~~

(70) (Blank); ~~Methyl 2-(1H-indazole-3-carboxamido)-3-methylbutanoate with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including, but not limited to, AMB, 5F AMB;~~

(71) (Blank); ~~Methyl 2-(1H-indazole-3-carboxamido)-3,3-dimethylbutanoate with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl-aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including, but not limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;~~

(72) (Blank); ~~Methyl 2-(1H-indole-3-carboxamido)-3-methylbutanoate with substitution on the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including, but not limited to, MMB018, MMB2201, and AMB-CHIMICA;~~

(73) (Blank); ~~Methyl 2-(1H-indole-3-carboxamido)-3,3-dimethylbutanoate with substitution on the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including, but not limited to, MDMA-CHIMICA;~~

(74) (Blank); ~~N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indazole-3-carboxamide with substitution on the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including, but not limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;~~

(75) (Blank); ~~N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-3-carboxamide with substitution on the~~

~~nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent: including, but not limited to, APP-PICA and 5-fluoro APP-PICA;~~

(76) 4-Acetoxy-N,N-dimethyltryptamine: trade name 4-AcO-DMT;

(77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade name 5-MeO-MIPT;

(78) 4-hydroxy Diethyltryptamine (4-HO-DET);

(79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);

(80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);

(81) 4-hydroxy-N-methyl-N-isopropyltryptamine (4-HO-MiPT);

(82) (Blank); ~~Fluorophenylpiperazine;~~

(83) Methoxetamine;

(84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-ethcathinone).

(e) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

- (1) mecloqualone;
- (2) methaqualone; and
- (3) gamma hydroxybutyric acid.

(f) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

- (1) Fenethylline;
- (2) N-ethylamphetamine;
- (3) Aminorex (some other names:

2-amino-5-phenyl-2-oxazoline; aminoxaphen;  
4-5-dihydro-5-phenyl-2-oxazamine) and its  
salts, optical isomers, and salts of optical isomers;

- (4) Methcathinone (some other names:

2-methylamino-1-phenylpropan-1-one;  
Ephedrone; 2-(methylamino)-propionophenone;  
alpha-(methylamino)propionophenone; N-methylcathinone;  
methcathinone; Monomethylpropion; UR 1431) and its  
salts, optical isomers, and salts of optical isomers;

- (5) Cathinone (some trade or other names:

2-aminopropionophenone; alpha-aminopropionophenone;  
2-amino-1-phenyl-propanone; norephedrone);

- (6) N,N-dimethylamphetamine (also known as:

N,N-alpha-trimethyl-benzeneethanamine;  
N,N-alpha-trimethylphenethylamine);

(7) (+ or -) cis-4-methylaminorex ((+ or -) cis-4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);

(8) 3,4-Methylenedioxypyrovalerone (MDPV);

(9) Halogenated amphetamines and methamphetamines - any compound derived from either amphetamine or methamphetamine through the substitution of a halogen on the phenyl ring, including, but not limited to, 2-fluoroamphetamine, 3-fluoroamphetamine and 4-fluoroamphetamine;

(10) Aminopropylbenzofuran (APB): including 4-(2-Aminopropyl) benzofuran, 5-(2-Aminopropyl)benzofuran, 6-(2-Aminopropyl) benzofuran, and 7-(2-Aminopropyl) benzofuran;

(11) Aminopropyldihydrobenzofuran (APDB): including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran, 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran, 6-(2-Aminopropyl)-2,3-dihydrobenzofuran, and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;

(12) Methylaminopropylbenzofuran (MAPB): including 4-(2-methylaminopropyl) benzofuran, 5-(2-methylaminopropyl)benzofuran, 6-(2-methylaminopropyl)benzofuran and 7-(2-methylaminopropyl)benzofuran; -

(13) Methylaminopropyldihydrobenzofuran (MAPDB): including 1-(2,3-dihydrobenzofuran-5-yl)-N-methylpropan-2-amine.

1 (g) Temporary listing of substances subject to emergency  
2 scheduling. Any material, compound, mixture, or preparation  
3 that contains any quantity of the following substances:

4 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide  
5 (benzylfentanyl), its optical isomers, isomers, salts, and  
6 salts of isomers;

7 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-  
8 phenylpropanamide (thenylfentanyl), its optical isomers,  
9 salts, and salts of isomers.

10 (h) Synthetic cathinones. Unless specifically excepted,  
11 any chemical compound which is not approved by the United  
12 States Food and Drug Administration or, if approved, is not  
13 dispensed or possessed in accordance with State or federal  
14 law, not including bupropion, structurally derived from  
15 2-aminopropan-1-one by substitution at the 1-position with  
16 either phenyl, naphthyl, or thiophene ring systems, whether or  
17 not the compound is further modified in one or more of the  
18 following ways:

19 (1) by substitution in the ring system to any extent  
20 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or  
21 halide substituents, whether or not further substituted in  
22 the ring system by one or more other univalent  
23 substituents. Examples of this class include, but are not  
24 limited to, 3,4-Methylenedioxycathinone (bk-MDA);

25 (2) by substitution at the 3-position with an acyclic  
26 alkyl substituent. Examples of this class include, but are



1 not limited to, 2-methylamino-1-phenylbutan-1-one  
2 (buphedrone); or

3 (3) by substitution at the 2-amino nitrogen atom with  
4 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by  
5 inclusion of the 2-amino nitrogen atom in a cyclic  
6 structure. Examples of this class include, but are not  
7 limited to, Dimethylcathinone, Ethcathinone, and  
8  $\alpha$ -Pyrrolidinopropiophenone ( $\alpha$ -PPP); or

9 Any other synthetic cathinone which is not approved by the  
10 United States Food and Drug Administration or, if approved, is  
11 not dispensed or possessed in accordance with State or federal  
12 law.

13 (i) Synthetic cannabinoids or piperazines. Any synthetic  
14 cannabinoid or piperazine which is not approved by the United  
15 States Food and Drug Administration or, if approved, which is  
16 not dispensed or possessed in accordance with State and  
17 federal law.

18 (1) As used in this Section, "synthetic cannabinoid"  
19 includes, but is not limited to, any compound, as  
20 identified in a report from an accredited forensic  
21 laboratory, that is structurally derived from any one or  
22 more of the following compounds:

23 (A) Any compound structurally derived from  
24 3-(1-naphthoyl)indole or  
25 1H-indol-3-yl-(1-naphthyl)methane by substitution at  
26 the nitrogen atom of the indole ring by alkyl,

haloalkyl, alkenyl, cycloalkylmethyl,  
cycloalkylethyl, aryl halide, alkyl aryl halide,  
1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl whether or not further  
substituted in the indole ring to any extent, whether  
or not substituted in the naphthyl ring to any extent.  
Examples of this structural class include, but are not  
limited to, JWH-018, AM-2201, JWH-175, JWH-184, and  
JWH-185;

(B) 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent. Examples of this structural class include, but are not limited to, JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;

(C) 1-(1-naphthylmethyl)indene by substitution at  
the 3-position of the indene ring by alkyl, haloalkyl,  
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl  
halide, alkyl aryl halide,  
1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl whether or not further

1 substituted in the indene ring to any extent, whether  
2 or not substituted in the naphthyl ring to any extent.  
3 Examples of this structural class include, but are not  
4 limited to, JWH-176;

5 (D) 3-phenylacetylindole by substitution at the  
6 nitrogen atom of the indole ring with alkyl,  
7 haloalkyl, alkenyl, cycloalkylmethyl,  
8 cycloalkylethyl, aryl halide, alkyl aryl halide,  
9 1-(N-methyl-2-piperidinyl)methyl, or  
10 2-(4-morpholinyl)ethyl, whether or not further  
11 substituted in the indole ring to any extent, whether  
12 or not substituted in the phenyl ring to any extent.  
13 Examples of this structural class include, but are not  
14 limited to, JWH-167, JWH-250, JWH-251, and RCS-8;

15 (E) 2-(3-hydroxycyclohexyl)phenol by substitution  
16 at the 5-position of the phenolic ring by alkyl,  
17 haloalkyl, alkenyl, cycloalkylmethyl,  
18 cycloalkylethyl, aryl halide, alkyl aryl halide,  
19 1-(N-methyl-2-piperidinyl)methyl, or  
20 2-(4-morpholinyl)ethyl, whether or not substituted in  
21 the cyclohexyl ring to any extent. Examples of this  
22 structural class include, but are not limited to, CP  
23 47, 497 and its C8 homologue (cannabicyclohexanol);

24 (F) 3-(benzoyl) indole with substitution at the  
25 nitrogen atom of the indole ring by an alkyl,  
26 haloalkyl, alkenyl, cycloalkylmethyl,

cycloalkylethyl, aryl halide, alkyl aryl halide,  
1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl group whether or not further  
substituted in the indole ring to any extent and  
whether or not substituted in the phenyl ring to any  
extent. Examples of this structural class include, but  
are not limited to, AM-630, AM-2233, AM-694,  
Pravadoline (WIN 48,098), and RCS-4;

(G) 3-cyclopropoylindole with substitution at the  
nitrogen atom of the indole ring by alkyl, haloalkyl,  
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl  
halide, alkyl aryl halide,  
1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl, whether or not further  
substituted on the indole ring to any extent, whether  
or not substituted on the cyclopropyl ring to any  
extent, including, but not limited to, XLR11, UR144,  
FUB-144;

(H) 3-adamantoylindole with substitution at the  
nitrogen atom of the indole ring by alkyl, haloalkyl,  
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl  
halide, alkyl aryl halide,  
1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl, whether or not further  
substituted on the indole ring to any extent, whether  
or not substituted on the adamantyl ring to any

1 extent, including, but not limited to, AB-001;

2 (I) N-(adamantyl)-indole-3-carboxamide with  
3 substitution at the nitrogen atom of the indole ring  
4 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
5 cycloalkylethyl, aryl halide, alkyl aryl halide,  
6 1-(N-methyl-2-piperidinyl)methyl, or  
7 2-(4-morpholinyl)ethyl, whether or not further  
8 substituted on the indole ring to any extent, whether  
9 or not substituted on the adamantyl ring to any  
10 extent, including, but not limited to, APICA/2NE-1,  
11 STS-135;

12 (J) N-(adamantyl)-indazole-3-carboxamide with  
13 substitution at a nitrogen atom of the indazole ring  
14 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
15 cycloalkylethyl, aryl halide, alkyl aryl halide,  
16 1-(N-methyl-2-piperidinyl)methyl, or  
17 2-(4-morpholinyl)ethyl, whether or not further  
18 substituted on the indazole ring to any extent,  
19 whether or not substituted on the adamantyl ring to  
20 any extent, including, but not limited to, AKB48,  
21 5F-AKB48;

22 (K) 1H-indole-3-carboxylic acid 8-quinolinyl ester  
23 with substitution at the nitrogen atom of the indole  
24 ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
25 cycloalkylethyl, aryl halide, alkyl aryl halide,  
26 1-(N-methyl-2-piperidinyl)methyl, or

2-(4-morpholinyl)ethyl, whether or not further substituted on the indole ring to any extent, whether or not substituted on the quinoline ring to any extent, including, but not limited to, PB22, 5F-PB22, FUB-PB-22;

(L) 3-(1-naphthoyl)indazole with substitution at the nitrogen atom of the indazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to, THJ-018, THJ-2201;

(M) 2-(1-naphthoyl)benzimidazole with substitution at the nitrogen atom of the benzimidazole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl, whether or not further substituted on the benzimidazole ring to any extent, whether or not substituted on the naphthyl ring to any extent, including, but not limited to, FUBIMINA;

(N) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-3-carboxamide with substitution on the

nitrogen atom of the indazole ring by alkyl,  
haloalkyl, alkenyl, cycloalkylmethyl,  
cycloalkylethyl, aryl halide, alkyl aryl halide,  
1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl, whether or not further  
substituted on the indazole ring to any extent,  
including, but not limited to, AB-PINACA, AB-FUBINACA,  
AB-CHMINACA;

(O) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-  
1H-indazole-3-carboxamide with substitution on the  
nitrogen atom of the indazole ring by alkyl,  
haloalkyl, alkenyl, cycloalkylmethyl,  
cycloalkylethyl, aryl halide, alkyl aryl halide,  
1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl, whether or not further  
substituted on the indazole ring to any extent,  
including, but not limited to, ADB-PINACA,  
ADB-FUBINACA;

(P) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-  
1H-indole-3-carboxamide with substitution on the  
nitrogen atom of the indole ring by alkyl, haloalkyl,  
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl  
halide, alkyl aryl halide,  
1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl, whether or not further  
substituted on the indole ring to any extent,

1 including, but not limited to, ADBICA, 5F-ADBICA;

2 (Q) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-  
3 indole-3-carboxamide with substitution on the nitrogen  
4 atom of the indole ring by alkyl, haloalkyl, alkenyl,  
5 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl  
6 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
7 2-(4-morpholinyl)ethyl, whether or not further  
8 substituted on the indole ring to any extent,  
9 including, but not limited to, ABICA, 5F-ABICA;

10 (R) Methyl 2-(1H-indazole-3-carboxamido)-  
11 3-methylbutanoate with substitution on the nitrogen  
12 atom of the indazole ring by alkyl, haloalkyl,  
13 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl  
14 halide, alkyl aryl halide,  
15 1-(N-methyl-2-piperidinyl)methyl, or  
16 2-(4-morpholinyl)ethyl, whether or not further  
17 substituted on the indazole ring to any extent,  
18 including, but not limited to, AMB, 5F-AMB;

19 (S) Methyl 2-(1H-indazole-3-carboxamido)-  
20 3,3-dimethylbutanoate with substitution on the  
21 nitrogen atom of the indazole ring by alkyl,  
22 haloalkyl, alkenyl, cycloalkylmethyl,  
23 cycloalkylethyl, aryl halide, alkyl aryl halide,  
24 1-(N-methyl-2-piperidinyl)methyl, or  
25 2-(4-morpholinyl)ethyl, whether or not further  
26 substituted on the indazole ring to any extent,



1 including, but not limited to, 5-fluoro-MDMB-PINACA,  
2 MDMB-FUBINACA;

3 (T) Methyl 2-(1H-indole-3-carboxamido)-3-  
4 methylbutanoate with substitution on the nitrogen atom  
5 of the indole ring by alkyl, haloalkyl, alkenyl,  
6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl  
7 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
8 2-(4-morpholinyl)ethyl, whether or not further  
9 substituted on the indole ring to any extent,  
10 including, but not limited to, MMB018, MMB2201, and  
11 AMB-CHMICA;

12 (U) Methyl 2-(1H-indole-3-carboxamido)-3,3-  
13 dimethylbutanoate with substitution on the nitrogen  
14 atom of the indole ring by alkyl, haloalkyl, alkenyl,  
15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl  
16 aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
17 2-(4-morpholinyl)ethyl, whether or not further  
18 substituted on the indazole indole ring to any extent,  
19 including, but not limited to, MDMB-CHMICA;

20 (V) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-  
21 indazole-3-carboxamide with substitution on the  
22 nitrogen atom of the indazole ring by alkyl,  
23 haloalkyl, alkenyl, cycloalkylmethyl,  
24 cycloalkylethyl, aryl halide, alkyl aryl halide,  
25 1-(N-methyl-2-piperidinyl)methyl, or  
26 2-(4-morpholinyl)ethyl, whether or not further

substituted on the indazole ring to any extent,  
including, but not limited to, APP-CHMINACA,  
5-fluoro-APP-PINACA;

(W) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-  
1H-indole-3-carboxamide with substitution on the  
nitrogen atom of the indole ring by alkyl, haloalkyl,  
alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl  
halide, alkyl aryl halide,  
1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl, whether or not further  
substituted on the indole ring to any extent,  
including, but not limited to, APP-PICA and  
5-fluoro-APP-PICA;

(X) 1H-indazole-3-carboxylic acid 8-quinolinyl  
ester with substitution at the nitrogen atom of the  
indazole ring by alkyl, haloalkyl, alkenyl,  
cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl  
aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or  
2-(4-morpholinyl)ethyl, whether or not further  
substituted on the inazdole ring to any extent,  
whether or not substituted on the quinoline ring to  
any extent, including, but not limited to, SDB-005,  
5-F-SDB-005;

(2) As used in this Section, "synthetic piperazine"  
includes, but is not limited to, any of the following  
compounds and their positional isomers:

1                   (A) N-Benzylpiperazine (BZP);

2                   (B) Trifluoromethylphenylpiperazine (TFMPP);

3                   (C) Fluorophenylpiperazine;

4                   (D) Chlorophenylpiperazine.

5           (j) Unless specifically excepted or listed in another  
6 schedule, any chemical compound which is not approved by the  
7 United States Food and Drug Administration or, if approved, is  
8 not dispensed or possessed in accordance with State or federal  
9 law, and is derived from the following structural classes and  
10 their salts:

11               (1) Benzodiazepine class: A fused 1,4-diazepine and  
12 benzene ring structure with a phenyl connected to the  
13 1,4-diazepine ring, with any substitution(s) or  
14 replacement(s) on the 1,4-diazepine or benzene ring, any  
15 substitution(s) on the phenyl ring, or any combination  
16 thereof. Examples of this class include but are not  
17 limited to: Clonazepam, Flualprazolam; or

18               (2) Thienodiazepine class: A fused 1,4-diazepine and  
19 thiophene ring structure with a phenyl connected to the  
20 1,4-diazepine ring, with any substitution(s) or  
21 replacement(s) on the 1,4-diazepine or thiophene ring, any  
22 substitution(s) on the phenyl ring, or any combination  
23 thereof. Examples of this class include but are not  
24 limited to: Etizolam.

25           (k) Fentanyl-related substances.

26               (1) As used in this Section, "fentanyl-related

1 substance" means any compound, as identified in a report  
2 from an accredited forensic laboratory, unless  
3 specifically excepted or listed under another schedule,  
4 that is not approved by the United States Food and Drug  
5 Administration or, if approved, is not dispensed or  
6 possessed in accordance with State or federal law and that  
7 is structurally derived from fentanyl  
8 (N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)-  
9 propanamide) by one or more of the following  
10 modifications:

11 (A) replacement of the phenyl portion of the  
12 phenethyl group by any monocycle, whether or not  
13 further substituted in or on the monocycle;

14 (B) substitution in or on the phenethyl group with  
15 alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl,  
16 amino, or nitro groups;

17 (C) substitution in or on the piperidine ring with  
18 alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo,  
19 haloalkyl, amino, or nitro groups;

20 (D) replacement of the aniline ring with any  
21 aromatic monocycle whether or not further substituted  
22 in or on the aromatic monocycle; or

23 (E) replacement of the N-propionyl group by  
24 another acyl group.

25 (2) "Fentanyl-related substance" includes, but is not  
26 limited to, the following substances:

1           (A) Acetyl-alpha-methylfentanyl;

2           (B) Alpha-methylfentanyl (N-(1-alpha-methyl-beta-  
3 phenyl)ethyl-4-piperidyl) propionanilide;  
4 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)  
5 piperidine;

6           (C) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-  
7 thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

8           (D) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-  
9 phenethyl)-4-piperidinyl]-N-phenylpropanamide

10           (E) 3-Methylfentanyl (N-[3-methyl-1-(2-  
11 phenylethyl)-4-piperidyl]-N-phenylpropanamide);

12           (F) 3-Methylthiofentanyl (N-[ (3-methyl-1-  
13 (2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide);

14           (G) Para-fluorofentanyl (N-(4-fluorophenyl)-  
15 N-[1-(2-phenethyl)-4-piperidinyl]propanamide);

16           (H) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-  
17 4-piperidinyl]-propanamide);

18           (I) Beta-hydroxy-3-methylfentanyl (other name:  
19 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-  
20 4-piperidinyl]-N-phenylpropanamide);

21           (J) Furanyl fentanyl (FU-F);

22           (K) Butyryl fentanyl;

23           (L) Valeryl fentanyl;

24           (M) Acetyl fentanyl;

25           (N) Beta-hydroxy-thiofentanyl;

26           (O) Acrylfentanyl (acryloylfentanyl);

1           (P) Cyclopropyl fentanyl;  
2           (Q) Crotonyl fentanyl;  
3           (R) Methoxyacetyl fentanyl;  
4           (S) Pentanoyl fentanyl;  
5           (T) Cyclopentyl fentanyl;  
6           (U) Isobutyryl fentanyl;  
7           (V) Benzodioxolefentanyl;  
8           (W) Tetrahydrofuran fentanyl.

9           (Source: P.A. 103-245, eff. 1-1-24.)

10           (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)

11           Sec. 206. (a) The controlled substances listed in this  
12           Section are included in Schedule II.

13           (b) Unless specifically excepted or unless listed in  
14           another schedule, any of the following substances whether  
15           produced directly or indirectly by extraction from substances  
16           of vegetable origin, or independently by means of chemical  
17           synthesis, or by combination of extraction and chemical  
18           synthesis:

19                 (1) Opium and opiates, and any salt, compound,  
20                 derivative or preparation of opium or opiate, excluding  
21                 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,  
22                 nalmefene, naloxone, and naltrexone, and their respective  
23                 salts, but including the following:

24                         (i) Raw Opium;

25                         (ii) Opium extracts;

- (iii) Opium fluid extracts;
- (iv) Powdered opium;
- (v) Granulated opium;
- (vi) Tincture of opium;
- (vii) Codeine;
- (viii) Ethylmorphine;
- (ix) Etorphine Hydrochloride;
- (x) Hydrocodone;
- (xi) Hydromorphone;
- (xii) Metopon;
- (xiii) Morphine;
- (xiii.5) 6-Monoacetylmorphine;
- (xiv) Oxycodone;
- (xv) Oxymorphone;
- (xv.5) Tapentadol;
- (xvi) Thebaine;
- (xvii) Thebaine-derived butorphanol.
- (xviii) Methorphan, except drug products containing dextromethorphan that may be dispensed pursuant to a prescription order of a practitioner and are sold in compliance with the safety and labeling standards as set forth by the United States Food and Drug Administration, or drug products containing dextromethorphan that are sold in solid, tablet, liquid, capsule, powder, thin film, or gel form and which are formulated, packaged, and sold in dosages

1           and concentrations for use as an over-the-counter drug  
2           product. For the purposes of this Section,  
3           "over-the-counter drug product" means a drug that is  
4           available to consumers without a prescription and sold  
5           in compliance with the safety and labeling standards  
6           as set forth by the United States Food and Drug  
7           Administration.

8           (2) Any salt, compound, isomer, derivative or  
9           preparation thereof which is chemically equivalent or  
10          identical with any of the substances referred to in  
11          subparagraph (1), but not including the isoquinoline  
12          alkaloids of opium;

13          (3) Opium poppy and poppy straw;

14          (4) Coca leaves and any salt, compound, isomer, salt  
15          of an isomer, derivative, or preparation of coca leaves  
16          including cocaine or ecgonine, and any salt, compound,  
17          isomer, derivative, or preparation thereof which is  
18          chemically equivalent or identical with any of these  
19          substances, but not including decocainized coca leaves or  
20          extractions of coca leaves which do not contain cocaine or  
21          ecgonine (for the purpose of this paragraph, the term  
22          "isomer" includes optical, ~~positional~~ and geometric  
23          isomers);

24          (5) Concentrate of poppy straw (the crude extract of  
25          poppy straw in either liquid, solid or powder form which  
26          contains the phenanthrine alkaloids of the opium poppy).



1 (c) Unless specifically excepted or unless listed in  
2 another schedule any of the following opiates, including their  
3 isomers, esters, ethers, salts, and salts of isomers, whenever  
4 the existence of these isomers, esters, ethers and salts is  
5 possible within the specific chemical designation, dextrorphan  
6 excepted:

- 7 (1) Alfentanil;
- 8 (1.1) Carfentanil;
- 9 (1.2) Thiafentanil;
- 10 (2) Alphaprodine;
- 11 (3) Anileridine;
- 12 (4) Bezitramide;
- 13 (5) Bulk Dextropropoxyphene (non-dosage forms);
- 14 (6) Dihydrocodeine;
- 15 (7) Diphenoxylate;
- 16 (8) Fentanyl;
- 17 (9) Sufentanil;
- 18 (9.5) Remifentanil;
- 19 (10) Isomethadone;
- 20 (11) (Blank);
- 21 (12) Levorphanol (Levorphan);
- 22 (13) Metazocine;
- 23 (14) Methadone;
- 24 (15) Methadone-Intermediate,
- 25 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
- 26 (16) Moramide-Intermediate,

1 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic  
2 acid;

3 (17) Pethidine (meperidine);

4 (18) Pethidine-Intermediate-A,  
5 4-cyano-1-methyl-4-phenylpiperidine;

6 (19) Pethidine-Intermediate-B,  
7 ethyl-4-phenylpiperidine-4-carboxylate;

8 (20) Pethidine-Intermediate-C,  
9 1-methyl-4-phenylpiperidine-4-carboxylic acid;

10 (21) Phenazocine;

11 (22) Piminodine;

12 (23) Racemethorphan;

13 (24) (Blank);

14 (25) Levo-alpha-acetylmethadol (some other names:  
15 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).

16 (d) Unless specifically excepted or unless listed in  
17 another schedule, any material, compound, mixture, or  
18 preparation which contains any quantity of the following  
19 substances having a stimulant effect on the central nervous  
20 system:

21 (1) Amphetamine, its salts, optical isomers, and salts  
22 of its optical isomers;

23 (2) Methamphetamine, its salts, isomers, and salts of  
24 its isomers;

25 (3) Phenmetrazine and its salts;

26 (4) Methylphenidate;

1 (5) Lisdexamfetamine.

2 (e) Unless specifically excepted or unless listed in  
3 another schedule, any material, compound, mixture, or  
4 preparation which contains any quantity of the following  
5 substances having a depressant effect on the central nervous  
6 system, including its salts, isomers, and salts of isomers  
7 whenever the existence of such salts, isomers, and salts of  
8 isomers is possible within the specific chemical designation:

9 (1) Amobarbital;

10 (2) Secobarbital;

11 (3) Pentobarbital;

12 (4) Pentazocine;

13 (5) Phencyclidine;

14 (6) Gluthethimide;

15 (7) (Blank).

16 (f) Unless specifically excepted or unless listed in  
17 another schedule, any material, compound, mixture, or  
18 preparation which contains any quantity of the following  
19 substances:

20 (1) Immediate precursor to amphetamine and  
21 methamphetamine:

22 (i) Phenylacetone

23 Some trade or other names: phenyl-2-propanone;

24 P2P; benzyl methyl ketone; methyl benzyl ketone.

25 (2) Immediate precursors to phencyclidine:

26 (i) 1-phenylcyclohexylamine;

1 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).

2 (3) Nabilone.

3 (Source: P.A. 100-368, eff. 1-1-18.)

4 (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208)

5 (Text of Section before amendment by P.A. 103-881)

6 Sec. 208. (a) The controlled substances listed in this  
7 Section are included in Schedule III.

8 (b) Unless specifically excepted or unless listed in  
9 another schedule, any material, compound, mixture, or  
10 preparation which contains any quantity of the following  
11 substances having a stimulant effect on the central nervous  
12 system, including its salts, isomers (whether optical  
13 position, or geometric), and salts of such isomers whenever  
14 the existence of such salts, isomers, and salts of isomers is  
15 possible within the specific chemical designation;

16 (1) Those compounds, mixtures, or preparations in  
17 dosage unit form containing any stimulant substances  
18 listed in Schedule II which compounds, mixtures, or  
19 preparations were listed on August 25, 1971, as excepted  
20 compounds under Title 21, Code of Federal Regulations,  
21 Section 308.32, and any other drug of the quantitative  
22 composition shown in that list for those drugs or which is  
23 the same except that it contains a lesser quantity of  
24 controlled substances;

25 (2) Benzphetamine;

1 (3) Chlorphentermine;

2 (4) Clortermine;

3 (5) Phendimetrazine.

4 (c) Unless specifically excepted or unless listed in  
5 another schedule, any material, compound, mixture, or  
6 preparation which contains any quantity of the following  
7 substances having a potential for abuse associated with a  
8 depressant effect on the central nervous system:

9 (1) Any compound, mixture, or preparation containing  
10 amobarbital, secobarbital, pentobarbital or any salt  
11 thereof and one or more other active medicinal ingredients  
12 which are not listed in any schedule;

13 (2) Any suppository dosage form containing  
14 amobarbital, secobarbital, pentobarbital or any salt of  
15 any of these drugs and approved by the Federal Food and  
16 Drug Administration for marketing only as a suppository;

17 (3) Any substance which contains any quantity of a  
18 derivative of barbituric acid, or any salt thereof:

19 (3.1) Aprobarbital;

20 (3.2) Butabarbital (secbutabarbital);

21 (3.3) Butalbital;

22 (3.4) Butobarbital (butethal);

23 (4) Chlorhexadol;

24 (5) Methyprylon;

25 (6) Sulfondiethylmethane;

26 (7) Sulfonethylmethane;

(8) Sulphonmethane;

(9) Lysergic acid;

(10) Lysergic acid amide;

(10.1) Tiletamine or zolazepam or both, or any salt of either of them.

Some trade or other names for a tiletamine-zolazepam combination product: Telazol.

Some trade or other names for Tiletamine:

2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

Some trade or other names for zolazepam:

4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-[3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrzapon.

(11) Any material, compound, mixture or preparation containing not more than 12.5 milligrams of pentazocine or any of its salts, per 325 milligrams of aspirin;

(12) Any material, compound, mixture or preparation containing not more than 12.5 milligrams of pentazocine or any of its salts, per 325 milligrams of acetaminophen;

(13) Any material, compound, mixture or preparation containing not more than 50 milligrams of pentazocine or any of its salts plus naloxone HCl USP 0.5 milligrams, per dosage unit;

(14) Ketamine;

(15) Thiopental.

(d) Nalorphine.

(d.5) Buprenorphine.

1 (e) Unless specifically excepted or unless listed in  
2 another schedule, any material, compound, mixture, or  
3 preparation containing limited quantities of any of the  
4 following narcotic drugs, or their salts calculated as the  
5 free anhydrous base or alkaloid, as set forth below:

6 (1) not more than 1.8 grams of codeine per 100  
7 milliliters or not more than 90 milligrams per dosage  
8 unit, with an equal or greater quantity of an isoquinoline  
9 alkaloid of opium;

10 (2) not more than 1.8 grams of codeine per 100  
11 milliliters or not more than 90 milligrams per dosage  
12 unit, with one or more active non-narcotic ingredients in  
13 recognized therapeutic amounts;

14 (3) (blank);

15 (4) (blank);

16 (5) not more than 1.8 grams of dihydrocodeine per 100  
17 milliliters or not more than 90 milligrams per dosage  
18 unit, with one or more active, non-narcotic ingredients in  
19 recognized therapeutic amounts;

20 (6) not more than 300 milligrams of ethylmorphine per  
21 100 milliliters or not more than 15 milligrams per dosage  
22 unit, with one or more active, non-narcotic ingredients in  
23 recognized therapeutic amounts;

24 (7) not more than 500 milligrams of opium per 100  
25 milliliters or per 100 grams, or not more than 25  
26 milligrams per dosage unit, with one or more active,

1 non-narcotic ingredients in recognized therapeutic  
2 amounts;

3 (8) not more than 50 milligrams of morphine per 100  
4 milliliters or per 100 grams with one or more active,  
5 non-narcotic ingredients in recognized therapeutic  
6 amounts.

7 (f) Anabolic steroids, except the following anabolic  
8 steroids that are exempt:

- 9 (1) Androgyn L.A.;
- 10 (2) Andro-Estro 90-4;
- 11 (3) depANDROGYN;
- 12 (4) DEPO-T.E.;
- 13 (5) depTESTROGEN;
- 14 (6) Duomone;
- 15 (7) DURATESTRIN;
- 16 (8) DUO-SPAN II;
- 17 (9) Estratest;
- 18 (10) Estratest H.S.;
- 19 (11) PAN ESTRA TEST;
- 20 (12) Premarin with Methyltestosterone;
- 21 (13) TEST-ESTRO Cypionates;
- 22 (14) Testosterone Cyp 50 Estradiol Cyp 2;
- 23 (15) Testosterone Cypionate-Estradiol Cypionate  
24 injection; and
- 25 (16) Testosterone Enanthate-Estradiol Valerate  
26 injection.



1 (g) Hallucinogenic substances.

2 (1) Dronabinol (synthetic) in sesame oil and  
3 encapsulated in a soft gelatin capsule in a U.S. Food and  
4 Drug Administration approved product. Some other names for  
5 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-  
6 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or  
7 (-)-delta-9-(trans)-tetrahydrocannabinol.

8 (2) (Reserved).

9 (h) The Department may except by rule any compound,  
10 mixture, or preparation containing any stimulant or depressant  
11 substance listed in subsection (b) from the application of all  
12 or any part of this Act if the compound, mixture, or  
13 preparation contains one or more active medicinal ingredients  
14 not having a stimulant or depressant effect on the central  
15 nervous system, and if the admixtures are included therein in  
16 combinations, quantity, proportion, or concentration that  
17 vitiate the potential for abuse of the substances which have a  
18 stimulant or depressant effect on the central nervous system.  
19 (Source: P.A. 100-368, eff. 1-1-18.)

20 (Text of Section after amendment by P.A. 103-881)

21 Sec. 208. (a) The controlled substances listed in this  
22 Section are included in Schedule III.

23 (b) Unless specifically excepted or unless listed in  
24 another schedule, any material, compound, mixture, or  
25 preparation which contains any quantity of the following

1 substances having a stimulant effect on the central nervous  
2 system, including its salts, isomers (whether optical  
3 position, or geometric), and salts of such isomers whenever  
4 the existence of such salts, isomers, and salts of isomers is  
5 possible within the specific chemical designation;

6 (1) Those compounds, mixtures, or preparations in  
7 dosage unit form containing any stimulant substances  
8 listed in Schedule II which compounds, mixtures, or  
9 preparations were listed on August 25, 1971, as excepted  
10 compounds under Title 21, Code of Federal Regulations,  
11 Section 308.32, and any other drug of the quantitative  
12 composition shown in that list for those drugs or which is  
13 the same except that it contains a lesser quantity of  
14 controlled substances;

15 (2) Benzphetamine;

16 (3) Chlorphentermine;

17 (4) Clortermine;

18 (5) Phendimetrazine.

19 (c) Unless specifically excepted or unless listed in  
20 another schedule, any material, compound, mixture, or  
21 preparation which contains any quantity of the following  
22 substances having a potential for misuse associated with a  
23 depressant effect on the central nervous system:

24 (1) Any compound, mixture, or preparation containing  
25 amobarbital, secobarbital, pentobarbital or any salt  
26 thereof and one or more other active medicinal ingredients

1 which are not listed in any schedule;

2 (2) Any suppository dosage form containing  
3 amobarbital, secobarbital, pentobarbital or any salt of  
4 any of these drugs and approved by the Federal Food and  
5 Drug Administration for marketing only as a suppository;

6 (3) Any substance which contains any quantity of a  
7 derivative of barbituric acid, or any salt thereof:

8 (3.1) Aprobarbital;

9 (3.2) Butabarbital (secbutabarbital);

10 (3.3) Butalbital;

11 (3.4) Butobarbital (butethal);

12 (4) Chlorhexadol;

13 (5) Methypylon;

14 (6) Sulfondiethylmethane;

15 (7) Sulfonethylmethane;

16 (8) Sulfonmethane;

17 (9) Lysergic acid;

18 (10) Lysergic acid amide;

19 (10.1) Tiletamine or zolazepam or both, or any salt of  
20 either of them.

21 Some trade or other names for a tiletamine-zolazepam  
22 combination product: Telazol.

23 Some trade or other names for Tiletamine:

24 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

25 Some trade or other names for zolazepam:

26 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-

1 [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrzapon.

2 (11) Any material, compound, mixture or preparation  
3 containing not more than 12.5 milligrams of pentazocine or  
4 any of its salts, per 325 milligrams of aspirin;

5 (12) Any material, compound, mixture or preparation  
6 containing not more than 12.5 milligrams of pentazocine or  
7 any of its salts, per 325 milligrams of acetaminophen;

8 (13) Any material, compound, mixture or preparation  
9 containing not more than 50 milligrams of pentazocine or  
10 any of its salts plus naloxone HCl USP 0.5 milligrams, per  
11 dosage unit;

12 (14) Ketamine;

13 (15) Thiopental; ~~-~~

14 (16) Xylazine.

15 (d) Nalorphine.

16 (d.5) Buprenorphine.

17 (e) Unless specifically excepted or unless listed in  
18 another schedule, any material, compound, mixture, or  
19 preparation containing limited quantities of any of the  
20 following narcotic drugs, or their salts calculated as the  
21 free anhydrous base or alkaloid, as set forth below:

22 (1) not more than 1.8 grams of codeine per 100  
23 milliliters or not more than 90 milligrams per dosage  
24 unit, with an equal or greater quantity of an isoquinoline  
25 alkaloid of opium;

26 (2) not more than 1.8 grams of codeine per 100

1 milliliters or not more than 90 milligrams per dosage  
2 unit, with one or more active non-narcotic ingredients in  
3 recognized therapeutic amounts;

4 (3) (blank);

5 (4) (blank);

6 (5) not more than 1.8 grams of dihydrocodeine per 100  
7 milliliters or not more than 90 milligrams per dosage  
8 unit, with one or more active, non-narcotic ingredients in  
9 recognized therapeutic amounts;

10 (6) not more than 300 milligrams of ethylmorphine per  
11 100 milliliters or not more than 15 milligrams per dosage  
12 unit, with one or more active, non-narcotic ingredients in  
13 recognized therapeutic amounts;

14 (7) not more than 500 milligrams of opium per 100  
15 milliliters or per 100 grams, or not more than 25  
16 milligrams per dosage unit, with one or more active,  
17 non-narcotic ingredients in recognized therapeutic  
18 amounts;

19 (8) not more than 50 milligrams of morphine per 100  
20 milliliters or per 100 grams with one or more active,  
21 non-narcotic ingredients in recognized therapeutic  
22 amounts.

23 (f) Anabolic steroids, except the following anabolic  
24 steroids that are exempt:

25 (1) Androgyn L.A.;

26 (2) Andro-Estro 90-4;

- 1 (3) depANDROGYN;
- 2 (4) DEPO-T.E.;
- 3 (5) depTESTROGEN;
- 4 (6) Duomone;
- 5 (7) DURATESTRIN;
- 6 (8) DUO-SPAN II;
- 7 (9) Estratest;
- 8 (10) Estratest H.S.;
- 9 (11) PAN ESTRA TEST;
- 10 (12) Premarin with Methyltestosterone;
- 11 (13) TEST-ESTRO Cypionates;
- 12 (14) Testosterone Cyp 50 Estradiol Cyp 2;
- 13 (15) Testosterone Cypionate-Estradiol Cypionate
- 14 injection; and
- 15 (16) Testosterone Enanthate-Estradiol Valerate
- 16 injection.

17 (g) Hallucinogenic substances.

18 (1) Dronabinol (synthetic) in sesame oil and  
19 encapsulated in a soft gelatin capsule in a U.S. Food and  
20 Drug Administration approved product. Some other names for  
21 dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro-  
22 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or  
23 (-)-delta-9-(trans)-tetrahydrocannabinol.

24 (2) (Reserved).

25 (h) The Department may except by rule any compound,  
26 mixture, or preparation containing any stimulant or depressant

1 substance listed in subsection (b) from the application of all  
2 or any part of this Act if the compound, mixture, or  
3 preparation contains one or more active medicinal ingredients  
4 not having a stimulant or depressant effect on the central  
5 nervous system, and if the admixtures are included therein in  
6 combinations, quantity, proportion, or concentration that  
7 vitiate the potential for misuse of the substances which have  
8 a stimulant or depressant effect on the central nervous  
9 system.

10 (Source: P.A. 103-881, eff. 1-1-25.)

11 Section 95. No acceleration or delay. Where this Act makes  
12 changes in a statute that is represented in this Act by text  
13 that is not yet or no longer in effect (for example, a Section  
14 represented by multiple versions), the use of that text does  
15 not accelerate or delay the taking effect of (i) the changes  
16 made by this Act or (ii) provisions derived from any other  
17 Public Act.

18 Section 99. Effective date. This Act takes effect January  
19 1, 2026.